{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:51:03Z","timestamp":1793224263644,"version":"4.5.0"},"reference-count":437,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474264, 82174170"],"award-info":[{"award-number":["82474264, 82174170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Municipal Government\u2019s \u201cThree Famous Health Project\u201d"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Asthma is a heterogeneous chronic airway disease arising from a complex interplay of genetic susceptibility and environmental exposures. Key pathobiological features include dysregulated immune responses (particularly type 2 inflammation), structural airway remodeling, and mucus hypersecretion. Recent advances have illuminated mechanisms from epithelial \u201calarmin\u201d cytokine release (TSLP, IL-33, IL-25) to downstream cellular networks involving Th2\/Th17 lymphocytes, group 2 innate lymphoid cells (ILC2s), eosinophils, and mast cells. These pathways converge on bronchial hyperresponsiveness and airflow obstruction. Traditional therapy with inhaled corticosteroids and bronchodilators has improved asthma control, yet many patients, especially those with non\u2013type 2-driven endotypes such as neutrophilic or obesity-related asthma, remain suboptimally controlled. This limitation has driven the development of precision medicine approaches that target specific cytokines and signaling cascades, including IgE, IL-5, IL-4\/13, and TSLP, as well as intracellular signaling processes such as JAK\u2013STAT. Parallel innovations in biomarkers such as FeNO, blood eosinophils, periostin, and multi-omics-based signatures facilitate patient stratification and prediction of treatment response. This comprehensive review synthesizes current knowledge from genetic and epigenetic foundations of asthma, through immunologic and neurogenic mechanisms, to translational advances in therapeutics from laboratory to clinic. We highlight the importance of endotyping and \u201ctreatable traits\u201d such as eosinophilia, mucus plugging, or small-airway dysfunction in guiding individualized therapy. The emerging paradigm aims not only for symptom control but also for disease modification and remission, leveraging biomarkers and multidisciplinary approaches to achieve long-term asthma control in a broad patient population.<\/jats:p>","DOI":"10.1038\/s41392-026-02853-8","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:02:16Z","timestamp":1786320136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanisms and therapeutic strategies of asthma: from bench to bedside"],"prefix":"10.1038","volume":"11","author":[{"given":"Cong","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-4431","authenticated-orcid":false,"given":"Maimaititusun","family":"Yalikun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-1111","authenticated-orcid":false,"given":"Yiwei","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-367X","authenticated-orcid":false,"given":"Jingcheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2853_CR1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","volume":"401","author":"C Porsbjerg","year":"2023","unstructured":"Porsbjerg, C., Melen, E., Lehtimaki, L. & Shaw, D. Asthma. Lancet 401, 858\u2013873 (2023).","journal-title":"Lancet"},{"key":"2853_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(25)00003-7","volume":"13","author":"GBD Asthma","year":"2025","unstructured":"Asthma, G. B. D. & Allergic Diseases, C. Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Respir. Med. 13, 425\u2013446 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12931-023-02475-6","volume":"24","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Respir. Res. 24, 169 (2023).","journal-title":"Respir. Res."},{"key":"2853_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-016-0029-3","volume":"3","author":"C Nunes","year":"2017","unstructured":"Nunes, C., Pereira, A. M. & Morais-Almeida, M. Asthma costs and social impact. Asthma Res. Pract. 3, 1 (2017).","journal-title":"Asthma Res. Pract."},{"key":"2853_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2015.11.002","volume":"111","author":"R Aalbers","year":"2016","unstructured":"Aalbers, R., Vogelmeier, C. & Kuna, P. Achieving asthma control with ICS\/LABA: a review of strategies for asthma management and prevention. Respir. Med. 111, 1\u20137 (2016).","journal-title":"Respir. Med."},{"key":"2853_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105189","volume":"160","author":"I Henderson","year":"2020","unstructured":"Henderson, I. et al. Why do some asthma patients respond poorly to glucocorticoid therapy? Pharm. Res. 160, 105189 (2020).","journal-title":"Pharm. Res."},{"key":"2853_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker, E. R. et al. Systematic literature review of systemic corticosteroid use for asthma management. Am. J. Respir. Crit. Care Med. 201, 276\u2013293 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/all.13985","volume":"75","author":"E Sze","year":"2020","unstructured":"Sze, E., Bhalla, A. & Nair, P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy 75, 311\u2013325 (2020).","journal-title":"Allergy"},{"key":"2853_CR9","doi-asserted-by":"crossref","unstructured":"Peri, F. et al. T2-low asthma: a discussed but still orphan disease. Biomedicines 11, 1226 (2023).","DOI":"10.3390\/biomedicines11041226"},{"key":"2853_CR10","doi-asserted-by":"publisher","first-page":"175346662110425","DOI":"10.1177\/17534666211042534","volume":"15","author":"GW Canonica","year":"2021","unstructured":"Canonica, G. W. et al. Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies. Ther. Adv. Respir. Dis. 15, 17534666211042534 (2021).","journal-title":"Ther. Adv. Respir. Dis."},{"key":"2853_CR11","doi-asserted-by":"crossref","unstructured":"Nwaru, B. I. et al. Overuse of short-acting beta(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 55, 1901872 (2020).","DOI":"10.1183\/13993003.01872-2019"},{"key":"2853_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.chest.2023.09.004","volume":"165","author":"SE Zaeh","year":"2024","unstructured":"Zaeh, S. E., Eakin, M. N. & Chupp, G. Implementing antiinflammatory reliever strategies in asthma: the evolving paradigm of asthma management. Chest 165, 250\u2013252 (2024).","journal-title":"Chest"},{"key":"2853_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jaip.2023.01.002","volume":"11","author":"R Beasley","year":"2023","unstructured":"Beasley, R., Bruce, P., Houghton, C. & Hatter, L. The ICS\/formoterol reliever therapy regimen in asthma: a review. J. Allergy Clin. Immunol. Pract. 11, 762\u2013772.e761 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2500\/aap.2015.36.3908","volume":"36","author":"DM Lang","year":"2015","unstructured":"Lang, D. M. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 36, 418\u2013424 (2015).","journal-title":"Allergy Asthma Proc."},{"key":"2853_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/cea.70166","volume":"56","author":"X Chen","year":"2026","unstructured":"Chen, X. et al. Management and research progress of severe asthma in China. Clin. Exp. Allergy 56, 147\u2013166 (2026).","journal-title":"Clin. Exp. Allergy"},{"key":"2853_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","volume":"197","author":"TF Carr","year":"2018","unstructured":"Carr, T. F., Zeki, A. A. & Kraft, M. Eosinophilic and noneosinophilic asthma. Am. J. Respir. Crit. Care Med. 197, 22\u201337 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/all.15609","volume":"78","author":"GM Gauvreau","year":"2023","unstructured":"Gauvreau, G. M. et al. Sounding the alarmins-the role of alarmin cytokines in asthma. Allergy 78, 402\u2013417 (2023).","journal-title":"Allergy"},{"key":"2853_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","volume":"199","author":"MC McGregor","year":"2019","unstructured":"McGregor, M. C., Krings, J. G., Nair, P. & Castro, M. Role of biologics in asthma. Am. J. Respir. Crit. Care Med. 199, 433\u2013445 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.rmed.2019.02.003","volume":"150","author":"P Katsaounou","year":"2019","unstructured":"Katsaounou, P. et al. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respir. Med. 150, 51\u201362 (2019).","journal-title":"Respir. Med."},{"key":"2853_CR20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41423-025-01357-9","volume":"22","author":"H Hammad","year":"2025","unstructured":"Hammad, H., Ahmed, E. & Lambrecht, B. N. Immunotherapy for asthma. Cell Mol. Immunol. 22, 1521\u20131532 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"2853_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren, J. et al. Tezepelumab in adults with uncontrolled asthma. N. Engl. J. Med. 377, 936\u2013946 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","volume":"390","author":"PG Gibson","year":"2017","unstructured":"Gibson, P. G. et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 390, 659\u2013668 (2017).","journal-title":"Lancet"},{"key":"2853_CR23","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.xcrm.2022.100857","volume":"3","author":"A Ray","year":"2022","unstructured":"Ray, A., Das, J. & Wenzel, S. E. Determining asthma endotypes and outcomes: complementing existing clinical practice with modern machine learning. Cell Rep. Med. 3, 100857 (2022).","journal-title":"Cell Rep. Med."},{"key":"2853_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1183\/09031936.99.13100299","volume":"13","author":"GH Koppelman","year":"1999","unstructured":"Koppelman, G. H., Los, H. & Postma, D. S. Genetic and environment in asthma: the answer of twin studies. Eur. Respir. J. 13, 2\u20134 (1999).","journal-title":"Eur. Respir. J."},{"issue":"Suppl 1","key":"2853_CR25","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1513\/AnnalsATS.201507-459MG","volume":"13","author":"C Ober","year":"2016","unstructured":"Ober, C. Asthma genetics in the post-GWAS era. Ann. Am. Thorac. Soc. 13(Suppl 1), S85\u201390 (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2853_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00742-5","volume":"12","author":"CM Lewis","year":"2020","unstructured":"Lewis, C. M. & Vassos, E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 12, 44 (2020).","journal-title":"Genome Med."},{"key":"2853_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747\u2013753 (2009).","journal-title":"Nature"},{"key":"2853_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaci.2017.12.974","volume":"142","author":"MM Stein","year":"2018","unstructured":"Stein, M. M. et al. A decade of research on the 17q12-21 asthma locus: piecing together the puzzle. J. Allergy Clin. Immunol. 142, 749\u2013764.e743 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nature06014","volume":"448","author":"MF Moffatt","year":"2007","unstructured":"Moffatt, M. F. et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448, 470\u2013473 (2007).","journal-title":"Nature"},{"key":"2853_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ai.2017.06.001","volume":"135","author":"S Das","year":"2017","unstructured":"Das, S., Miller, M. & Broide, D. H. Chromosome 17q21 genes ORMDL3 and GSDMB in asthma and immune diseases. Adv. Immunol. 135, 1\u201352 (2017).","journal-title":"Adv. Immunol."},{"key":"2853_CR31","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJM199712113372403","volume":"337","author":"GK Hershey","year":"1997","unstructured":"Hershey, G. K. et al. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N. Engl. J. Med. 337, 1720\u20131725 (1997).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaci.2009.11.018","volume":"125","author":"X Li","year":"2010","unstructured":"Li, X. et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR\/DQ regions. J. Allergy Clin. Immunol. 125, 328\u2013335.e311 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12931-019-1006-1","volume":"20","author":"HF Li","year":"2019","unstructured":"Li, H. F. et al. Association between ADAM33 polymorphisms and asthma risk: a systematic review and meta-analysis. Respir. Res. 20, 38 (2019).","journal-title":"Respir. Res."},{"key":"2853_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41588-017-0014-7","volume":"50","author":"F Demenais","year":"2018","unstructured":"Demenais, F. et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nat. Genet. 50, 42\u201353 (2018).","journal-title":"Nat. Genet."},{"key":"2853_CR35","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1093\/hmg\/ddz175","volume":"28","author":"A Johansson","year":"2019","unstructured":"Johansson, A., Rask-Andersen, M., Karlsson, T. & Ek, W. E. Genome-wide association analysis of 350000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema. Hum. Mol. Genet. 28, 4022\u20134041 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"2853_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14144-8","volume":"11","author":"TA Olafsdottir","year":"2020","unstructured":"Olafsdottir, T. A. et al. Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis. Nat. Commun. 11, 393 (2020).","journal-title":"Nat. Commun."},{"key":"2853_CR37","doi-asserted-by":"publisher","first-page":"e1006659","DOI":"10.1371\/journal.pgen.1006659","volume":"13","author":"D Smith","year":"2017","unstructured":"Smith, D. et al. A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet. 13, e1006659 (2017).","journal-title":"PLoS Genet."},{"key":"2853_CR38","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaci.2019.05.017","volume":"144","author":"FN Dijk","year":"2019","unstructured":"Dijk, F. N. et al. Genetic risk scores do not improve asthma prediction in childhood. J. Allergy Clin. Immunol. 144, 857\u2013860.e857 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(13)70101-2","volume":"1","author":"DW Belsky","year":"2013","unstructured":"Belsky, D. W. et al. Polygenic risk and the development and course of asthma: an analysis of data from a four-decade longitudinal study. Lancet Respir. Med. 1, 453\u2013461 (2013).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR40","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/cea.14007","volume":"51","author":"JE Sordillo","year":"2021","unstructured":"Sordillo, J. E. et al. A polygenic risk score for asthma in a large racially diverse population. Clin. Exp. Allergy 51, 1410\u20131420 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"2853_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2022.03.035","volume":"150","author":"B Namjou","year":"2022","unstructured":"Namjou, B. et al. Multiancestral polygenic risk score for pediatric asthma. J. Allergy Clin. Immunol. 150, 1086\u20131096 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100212","volume":"2","author":"K Tsuo","year":"2022","unstructured":"Tsuo, K. et al. Multi-ancestry meta-analysis of asthma identifies novel associations and highlights the value of increased power and diversity. Cell Genom. 2, 100212 (2022).","journal-title":"Cell Genom."},{"key":"2853_CR43","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/all.12683","volume":"70","author":"X Li","year":"2015","unstructured":"Li, X. et al. eQTL of bronchial epithelial cells and bronchial alveolar lavage deciphers GWAS-identified asthma genes. Allergy 70, 1309\u20131318 (2015).","journal-title":"Allergy"},{"key":"2853_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01058-2","volume":"14","author":"SM Clay","year":"2022","unstructured":"Clay, S. M. et al. Fine-mapping studies distinguish genetic risks for childhood- and adult-onset asthma in the HLA region. Genome Med. 14, 55 (2022).","journal-title":"Genome Med."},{"key":"2853_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/pr.2013.186","volume":"75","author":"JG Ono","year":"2014","unstructured":"Ono, J. G., Worgall, T. S. & Worgall, S. 17q21 locus and ORMDL3: an increased risk for childhood asthma. Pediatr. Res 75, 165\u2013170 (2014).","journal-title":"Pediatr. Res"},{"key":"2853_CR46","doi-asserted-by":"publisher","first-page":"16648","DOI":"10.1073\/pnas.1204151109","volume":"109","author":"M Miller","year":"2012","unstructured":"Miller, M. et al. ORMDL3 is an inducible lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6. Proc. Natl. Acad. Sci. USA 109, 16648\u201316653 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2853_CR47","doi-asserted-by":"crossref","unstructured":"Dijk, F. N. et al. Genetic regulation of IL1RL1 methylation and IL1RL1-a protein levels in asthma. Eur. Respir J. 51, 1701377 (2018).","DOI":"10.1183\/13993003.01377-2017"},{"key":"2853_CR48","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jaci.2017.11.040","volume":"142","author":"RA Panganiban","year":"2018","unstructured":"Panganiban, R. A. et al. A functional splice variant associated with decreased asthma risk abolishes the ability of gasdermin B to induce epithelial cell pyroptosis. J. Allergy Clin. Immunol. 142, 1469\u20131478.e1462 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR49","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s42003-021-02227-6","volume":"4","author":"K Valette","year":"2021","unstructured":"Valette, K. et al. Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank. Commun. Biol. 4, 700 (2021).","journal-title":"Commun. Biol."},{"key":"2853_CR50","doi-asserted-by":"crossref","unstructured":"Fakhar, M., Gul, M. & Li, W. Structural and functional studies on key epigenetic regulators in asthma. Biomolecules. 15, 1255 (2025).","DOI":"10.3390\/biom15091255"},{"key":"2853_CR51","doi-asserted-by":"crossref","unstructured":"Polverino, F. & Sin, D. D. The developmental origins of asthma and COPD. Annu. Rev. Physiol. 88, 513\u2013535 (2025).","DOI":"10.1146\/annurev-physiol-042924-084007"},{"key":"2853_CR52","doi-asserted-by":"crossref","unstructured":"Hoang, T. T. et al. Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study. Eur. Respir. J. 56, 2000217 (2020).","DOI":"10.1183\/13993003.00217-2020"},{"key":"2853_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaci.2015.01.025","volume":"136","author":"IV Yang","year":"2015","unstructured":"Yang, I. V. et al. DNA methylation and childhood asthma in the inner city. J. Allergy Clin. Immunol. 136, 69\u201380 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90151","volume":"1","author":"J Nicodemus-Johnson","year":"2016","unstructured":"Nicodemus-Johnson, J. et al. DNA methylation in lung cells is associated with asthma endotypes and genetic risk. JCI Insight 1, e90151 (2016).","journal-title":"JCI Insight"},{"key":"2853_CR55","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/cea.13403","volume":"49","author":"A Edris","year":"2019","unstructured":"Edris, A., den Dekker, H. T., Melen, E. & Lahousse, L. Epigenome-wide association studies in asthma: a systematic review. Clin. Exp. Allergy 49, 953\u2013968 (2019).","journal-title":"Clin. Exp. Allergy"},{"key":"2853_CR56","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000489765","volume":"83","author":"V Kogan","year":"2018","unstructured":"Kogan, V. et al. Genetic-epigenetic interactions in asthma revealed by a genome-wide gene-centric search. Hum. Hered. 83, 130\u2013152 (2018).","journal-title":"Hum. Hered."},{"key":"2853_CR57","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ajhg.2016.02.019","volume":"98","author":"BR Joubert","year":"2016","unstructured":"Joubert, B. R. et al. DNA methylation in newborns and maternal smoking in pregnancy: genome-wide consortium meta-analysis. Am. J. Hum. Genet. 98, 680\u2013696 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"2853_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01686-8","volume":"18","author":"M Vives-Usano","year":"2020","unstructured":"Vives-Usano, M. et al. In utero and childhood exposure to tobacco smoke and multi-layer molecular signatures in children. BMC Med. 18, 243 (2020).","journal-title":"BMC Med."},{"key":"2853_CR59","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaci.2012.10.042","volume":"131","author":"KJ Brunst","year":"2013","unstructured":"Brunst, K. J. et al. Forkhead box protein 3 (FOXP3) hypermethylation is associated with diesel exhaust exposure and risk for childhood asthma. J. Allergy Clin. Immunol. 131, 592\u2013594 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR60","doi-asserted-by":"publisher","first-page":"e4488","DOI":"10.1371\/journal.pone.0004488","volume":"4","author":"F Perera","year":"2009","unstructured":"Perera, F. et al. Relation of DNA methylation of 5\u2019-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. PLoS ONE 4, e4488 (2009).","journal-title":"PLoS ONE"},{"key":"2853_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01049-x","volume":"13","author":"M Sheikhpour","year":"2021","unstructured":"Sheikhpour, M., Maleki, M., Ebrahimi Vargoorani, M. & Amiri, V. A review of epigenetic changes in asthma: methylation and acetylation. Clin. Epigenet. 13, 65 (2021).","journal-title":"Clin. Epigenet."},{"key":"2853_CR62","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1183\/09031936.05.00117504","volume":"25","author":"PJ Barnes","year":"2005","unstructured":"Barnes, P. J., Adcock, I. M. & Ito, K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 25, 552\u2013563 (2005).","journal-title":"Eur. Respir. J."},{"key":"2853_CR63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jaci.2022.06.002","volume":"150","author":"S Sharma","year":"2022","unstructured":"Sharma, S., Yang, I. V. & Schwartz, D. A. Epigenetic regulation of immune function in asthma. J. Allergy Clin. Immunol. 150, 259\u2013265 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR64","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jaci.2007.12.1156","volume":"121","author":"P Bhavsar","year":"2008","unstructured":"Bhavsar, P., Ahmad, T. & Adcock, I. M. The role of histone deacetylases in asthma and allergic diseases. J. Allergy Clin. Immunol. 121, 580\u2013584 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1084\/jem.20050466","volume":"203","author":"K Ito","year":"2006","unstructured":"Ito, K. et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203, 7\u201313 (2006).","journal-title":"J. Exp. Med."},{"key":"2853_CR66","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1378\/chest.13-0835","volume":"145","author":"Y Kobayashi","year":"2014","unstructured":"Kobayashi, Y. et al. Passive smoking impairs histone deacetylase-2 in children with severe asthma. Chest 145, 305\u2013312 (2014).","journal-title":"Chest"},{"key":"2853_CR67","first-page":"3425","volume":"19","author":"XJ Sun","year":"2020","unstructured":"Sun, X. J. et al. Theophylline and dexamethasone in combination reduce inflammation and prevent the decrease in HDAC2 expression seen in monocytes exposed to cigarette smoke extract. Exp. Ther. Med. 19, 3425\u20133431 (2020).","journal-title":"Exp. Ther. Med."},{"key":"2853_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1165\/rcmb.2015-0050TR","volume":"54","author":"CD Kidd","year":"2016","unstructured":"Kidd, C. D., Thompson, P. J., Barrett, L. & Baltic, S. Histone modifications and asthma. The interface of the epigenetic and genetic landscapes. Am. J. Respir. Cell Mol. Biol. 54, 3\u201312 (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11882-022-01050-1","volume":"22","author":"R Sharma","year":"2022","unstructured":"Sharma, R., Tiwari, A. & McGeachie, M. J. Recent miRNA research in asthma. Curr. Allergy Asthma Rep. 22, 231\u2013258 (2022).","journal-title":"Curr. Allergy Asthma Rep."},{"key":"2853_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1753425920901563","volume":"27","author":"S ElKashef","year":"2021","unstructured":"ElKashef, S., Ahmad, S. E., Soliman, Y. M. A. & Mostafa, M. S. Role of microRNA-21 and microRNA-155 as biomarkers for bronchial asthma. Innate Immun. 27, 61\u201369 (2021).","journal-title":"Innate Immun."},{"key":"2853_CR71","first-page":"211","volume":"8","author":"A Sufianov","year":"2023","unstructured":"Sufianov, A. et al. Studies on the role of non-coding RNAs in controlling the activity of T cells in asthma. Noncod. RNA Res. 8, 211\u2013217 (2023).","journal-title":"Noncod. RNA Res."},{"key":"2853_CR72","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3389\/fimmu.2018.02512","volume":"9","author":"HR Gibbons","year":"2018","unstructured":"Gibbons, H. R. et al. Divergent lncRNA GATA3-AS1 regulates GATA3 Transcription in T-Helper 2 Cells. Front Immunol. 9, 2512 (2018).","journal-title":"Front Immunol."},{"key":"2853_CR73","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.chest.2018.10.038","volume":"155","author":"KA Kaczmarek","year":"2019","unstructured":"Kaczmarek, K. A., Clifford, R. L. & Knox, A. J. Epigenetic changes in airway smooth muscle as a driver of airway inflammation and remodeling in asthma. Chest 155, 816\u2013824 (2019).","journal-title":"Chest"},{"key":"2853_CR74","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41588-022-01252-3","volume":"55","author":"F Wu","year":"2023","unstructured":"Wu, F. et al. Spurious transcription causing innate immune responses is prevented by 5-hydroxymethylcytosine. Nat. Genet. 55, 100\u2013111 (2023).","journal-title":"Nat. Genet."},{"key":"2853_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1165\/rcmb.2017-0445OC","volume":"60","author":"B Tian","year":"2019","unstructured":"Tian, B. et al. Efficacy of novel highly specific bromodomain-containing protein 4 inhibitors in innate inflammation-driven airway remodeling. Am. J. Respir. Cell Mol. Biol. 60, 68\u201383 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/srep43139","volume":"7","author":"ML Manni","year":"2017","unstructured":"Manni, M. L. et al. Bromodomain and extra-terminal protein inhibition attenuates neutrophil-dominant allergic airway disease. Sci. Rep. 7, 43139 (2017).","journal-title":"Sci. Rep."},{"key":"2853_CR77","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.jaci.2011.12.963","volume":"129","author":"S Brand","year":"2012","unstructured":"Brand, S. et al. DNA methylation of TH1\/TH2 cytokine genes affects sensitization and progress of experimental asthma. J. Allergy Clin. Immunol. 129, 1602\u20131610.e1606 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR78","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000343030","volume":"160","author":"CJ Wu","year":"2013","unstructured":"Wu, C. J. et al. The DNA methylation inhibitor 5-azacytidine increases regulatory T cells and alleviates airway inflammation in ovalbumin-sensitized mice. Int Arch. Allergy Immunol. 160, 356\u2013364 (2013).","journal-title":"Int Arch. Allergy Immunol."},{"key":"2853_CR79","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3349\/ymj.2015.56.4.877","volume":"56","author":"JU Lee","year":"2015","unstructured":"Lee, J. U., Kim, J. D. & Park, C. S. Gene-environment interactions in asthma: genetic and epigenetic effects. Yonsei Med. J. 56, 877\u2013886 (2015).","journal-title":"Yonsei Med. J."},{"key":"2853_CR80","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/epi.12.32","volume":"4","author":"MT Salam","year":"2012","unstructured":"Salam, M. T., Zhang, Y. & Begum, K. Epigenetics and childhood asthma: current evidence and future research directions. Epigenomics 4, 415\u2013429 (2012).","journal-title":"Epigenomics"},{"key":"2853_CR81","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-021-00538-7","volume":"21","author":"CA Akdis","year":"2021","unstructured":"Akdis, C. A. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat. Rev. Immunol. 21, 739\u2013751 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2853_CR82","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jaci.2020.08.026","volume":"147","author":"HHF Tang","year":"2021","unstructured":"Tang, H. H. F. et al. The intersect of genetics, environment, and microbiota in asthma-perspectives and challenges. J. Allergy Clin. Immunol. 147, 781\u2013793 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR83","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.jaci.2019.07.029","volume":"144","author":"J Krusche","year":"2019","unstructured":"Krusche, J. et al. TNF-alpha-induced protein 3 is a key player in childhood asthma development and environment-mediated protection. J. Allergy Clin. Immunol. 144, 1684\u20131696.e1612 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR84","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1126\/science.aac6623","volume":"349","author":"MJ Schuijs","year":"2015","unstructured":"Schuijs, M. J. et al. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science 349, 1106\u20131110 (2015).","journal-title":"Science"},{"key":"2853_CR85","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai, W. et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct. Target Ther. 9, 332 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2853_CR86","doi-asserted-by":"crossref","unstructured":"Kierbiedz-Guzik, N. & Sozanska, B. miRNAs as modern biomarkers in asthma therapy. Int. J. Mol. Sci. 24, 11499 (2023).","DOI":"10.3390\/ijms241411499"},{"key":"2853_CR87","doi-asserted-by":"crossref","unstructured":"Fan, Y. & Yang, Z. Inhaled siRNA formulations for respiratory diseases: from basic research to clinical application. Pharmaceutics. 14, 1193(2022).","DOI":"10.3390\/pharmaceutics14061193"},{"key":"2853_CR88","doi-asserted-by":"publisher","first-page":"8800","DOI":"10.1073\/pnas.0912186107","volume":"107","author":"J DeVincenzo","year":"2010","unstructured":"DeVincenzo, J. et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 107, 8800\u20138805 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2853_CR89","doi-asserted-by":"publisher","first-page":"230044","DOI":"10.1183\/20734735.0044-2023","volume":"19","author":"A Guillien","year":"2023","unstructured":"Guillien, A., Ghosh, M., Gille, T. & Dumas, O. The exposome concept: how has it changed our understanding of environmental causes of chronic respiratory diseases? Breathe 19, 230044 (2023).","journal-title":"Breathe"},{"key":"2853_CR90","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2020.01.007","volume":"52","author":"W Barcik","year":"2020","unstructured":"Barcik, W., Boutin, R. C. T., Sokolowska, M. & Finlay, B. B. The role of lung and gut microbiota in the pathology of asthma. Immunity 52, 241\u2013255 (2020).","journal-title":"Immunity"},{"key":"2853_CR91","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00281-019-00775-y","volume":"42","author":"K Hufnagl","year":"2020","unstructured":"Hufnagl, K., Pali-Scholl, I., Roth-Walter, F. & Jensen-Jarolim, E. Dysbiosis of the gut and lung microbiome has a role in asthma. Semin. Immunopathol. 42, 75\u201393 (2020).","journal-title":"Semin. Immunopathol."},{"key":"2853_CR92","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jaci.2025.12.1005","volume":"157","author":"H Miyachi","year":"2026","unstructured":"Miyachi, H. et al. Interactions between host genetics and gut microbiome influence susceptibility to childhood asthma and lung function. J. Allergy Clin. Immunol. 157, 868\u2013878 (2026).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR93","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/all.13660","volume":"74","author":"C Roduit","year":"2019","unstructured":"Roduit, C. et al. High levels of butyrate and propionate in early life are associated with protection against atopy. Allergy 74, 799\u2013809 (2019).","journal-title":"Allergy"},{"key":"2853_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02573-2","volume":"9","author":"J Stokholm","year":"2018","unstructured":"Stokholm, J. et al. Maturation of the gut microbiome and risk of asthma in childhood. Nat. Commun. 9, 141 (2018).","journal-title":"Nat. Commun."},{"key":"2853_CR95","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-025-02263-2","volume":"10","author":"B Yu","year":"2025","unstructured":"Yu, B. et al. Microbiota-derived butyrate alleviates asthma via inhibiting Tfh13-mediated IgE production. Signal Transduct. Target Ther. 10, 181 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2853_CR96","doi-asserted-by":"publisher","first-page":"307ra152","DOI":"10.1126\/scitranslmed.aab2271","volume":"7","author":"MC Arrieta","year":"2015","unstructured":"Arrieta, M. C. et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 7, 307ra152 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2853_CR97","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaci.2017.02.004","volume":"139","author":"KF Chung","year":"2017","unstructured":"Chung, K. F. Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment? J. Allergy Clin. Immunol. 139, 1071\u20131081 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR98","doi-asserted-by":"crossref","unstructured":"Dickson, R. P. et al. Bacterial topography of the healthy human lower respiratory tract. mBio. 8, 1 (2017).","DOI":"10.1128\/mBio.02287-16"},{"key":"2853_CR99","doi-asserted-by":"publisher","first-page":"e1004923","DOI":"10.1371\/journal.ppat.1004923","volume":"11","author":"RP Dickson","year":"2015","unstructured":"Dickson, R. P. & Huffnagle, G. B. The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathog. 11, e1004923 (2015).","journal-title":"PLoS Pathog."},{"key":"2853_CR100","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1183\/13993003.00405-2015","volume":"47","author":"JL Simpson","year":"2016","unstructured":"Simpson, J. L. et al. Airway dysbiosis: haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur. Respir. J. 47, 792\u2013800 (2016).","journal-title":"Eur. Respir. J."},{"key":"2853_CR101","doi-asserted-by":"crossref","unstructured":"Gibson, P. G. et al. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Res. 5, 00056\u20132019 (2019).","DOI":"10.1183\/23120541.00056-2019"},{"key":"2853_CR102","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJM199705083361904","volume":"336","author":"DL Rosenstreich","year":"1997","unstructured":"Rosenstreich, D. L. et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N. Engl. J. Med. 336, 1356\u20131363 (1997).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR103","doi-asserted-by":"publisher","first-page":"e13807","DOI":"10.1111\/pai.13807","volume":"33","author":"R Frei","year":"2022","unstructured":"Frei, R., Heye, K. & Roduit, C. Environmental influences on childhood allergies and asthma - the Farm effect. Pediatr. Allergy Immunol. 33, e13807 (2022).","journal-title":"Pediatr. Allergy Immunol."},{"key":"2853_CR104","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1508749","volume":"375","author":"MM Stein","year":"2016","unstructured":"Stein, M. M. et al. Innate immunity and asthma risk in Amish and Hutterite farm children. N. Engl. J. Med. 375, 411\u2013421 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR105","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.1016\/S2542-5196(24)00279-1","volume":"8","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. Ambient air pollution exposure and adult asthma incidence: a systematic review and meta-analysis. Lancet Planet Health 8, e1065\u2013e1078 (2024).","journal-title":"Lancet Planet Health"},{"key":"2853_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2020.114600","volume":"263","author":"M de Homdedeu","year":"2020","unstructured":"de Homdedeu, M. et al. The immunomodulatory effects of diesel exhaust particles in asthma. Environ. Pollut. 263, 114600 (2020).","journal-title":"Environ. Pollut."},{"key":"2853_CR107","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaci.2006.06.006","volume":"118","author":"RC Chan","year":"2006","unstructured":"Chan, R. C. et al. Pro-oxidative diesel exhaust particle chemicals inhibit LPS-induced dendritic cell responses involved in T-helper differentiation. J. Allergy Clin. Immunol. 118, 455\u2013465 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR108","doi-asserted-by":"publisher","first-page":"103336","DOI":"10.1016\/j.iccn.2022.103336","volume":"74","author":"T Vieceli","year":"2023","unstructured":"Vieceli, T. et al. Impact of air pollution on respiratory microbiome: a narrative review. Intensive Crit. Care Nurs. 74, 103336 (2023).","journal-title":"Intensive Crit. Care Nurs."},{"key":"2853_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83577-3","volume":"11","author":"M Prunicki","year":"2021","unstructured":"Prunicki, M. et al. Air pollution exposure is linked with methylation of immunoregulatory genes, altered immune cell profiles, and increased blood pressure in children. Sci. Rep. 11, 4067 (2021).","journal-title":"Sci. Rep."},{"key":"2853_CR110","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaip.2022.01.006","volume":"10","author":"DJ Jackson","year":"2022","unstructured":"Jackson, D. J. & Gern, J. E. Rhinovirus infections and their roles in asthma: etiology and exacerbations. J. Allergy Clin. Immunol. Pract. 10, 673\u2013681 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR111","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0140-6736(23)00811-5","volume":"401","author":"C Rosas-Salazar","year":"2023","unstructured":"Rosas-Salazar, C. et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet 401, 1669\u20131680 (2023).","journal-title":"Lancet"},{"key":"2853_CR112","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1164\/rccm.201406-1039OC","volume":"190","author":"DJ Jackson","year":"2014","unstructured":"Jackson, D. J. et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am. J. Respir. Crit. Care Med. 190, 1373\u20131382 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR113","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.3389\/fimmu.2018.02640","volume":"9","author":"S Hanada","year":"2018","unstructured":"Hanada, S., Pirzadeh, M., Carver, K. Y. & Deng, J. C. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front. Immunol. 9, 2640 (2018).","journal-title":"Front. Immunol."},{"key":"2853_CR114","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1164\/rccm.201302-0341OC","volume":"188","author":"PL Molyneaux","year":"2013","unstructured":"Molyneaux, P. L. et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 188, 1224\u20131231 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR115","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1164\/rccm.201203-0501OC","volume":"186","author":"A Neuman","year":"2012","unstructured":"Neuman, A. et al. Maternal smoking in pregnancy and asthma in preschool children: a pooled analysis of eight birth cohorts. Am. J. Respir. Crit. Care Med. 186, 1037\u20131043 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR116","doi-asserted-by":"crossref","unstructured":"Nakamura, A., Francois, O. & Lepeule, J. Epigenetic alterations of maternal tobacco smoking during pregnancy: a narrative review. Int. J. Environ Res. Public Health. 18, 5083 (2021).","DOI":"10.3390\/ijerph18105083"},{"key":"2853_CR117","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2217\/epi.13.63","volume":"5","author":"JZ Maccani","year":"2013","unstructured":"Maccani, J. Z. et al. Placental DNA methylation alterations associated with maternal tobacco smoking at the RUNX3 gene are also associated with gestational age. Epigenomics 5, 619\u2013630 (2013).","journal-title":"Epigenomics"},{"key":"2853_CR118","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1164\/rccm.200511-1746OC","volume":"175","author":"SC Lazarus","year":"2007","unstructured":"Lazarus, S. C. et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am. J. Respir. Crit. Care Med. 175, 783\u2013790 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR119","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/resp.70200","volume":"31","author":"J Errasti Viader","year":"2026","unstructured":"Errasti Viader, J. et al. Association between Mediterranean diet and the incidence of adult-onset asthma in the SUN project: a Spanish prospective cohort study. Respirology 31, 352\u2013360 (2026).","journal-title":"Respirology"},{"key":"2853_CR120","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.immuni.2019.09.020","volume":"51","author":"A Christ","year":"2019","unstructured":"Christ, A., Lauterbach, M. & Latz, E. Western diet and the immune system: an inflammatory connection. Immunity 51, 794\u2013811 (2019).","journal-title":"Immunity"},{"key":"2853_CR121","doi-asserted-by":"publisher","first-page":"785835","DOI":"10.1155\/2013\/785835","volume":"2013","author":"A Sood","year":"2013","unstructured":"Sood, A. & Shore, S. A. Adiponectin, leptin, and resistin in asthma: basic mechanisms through population studies. J. Allergy 2013, 785835 (2013).","journal-title":"J. Allergy"},{"key":"2853_CR122","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. Adiponectin restrains ILC2 activation by AMPK-mediated feedback inhibition of IL-33 signaling. J. Exp. Med. 218, e20191054 (2021).","DOI":"10.1084\/jem.20191054"},{"key":"2853_CR123","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4168\/aair.2011.3.3.157","volume":"3","author":"O Vandenplas","year":"2011","unstructured":"Vandenplas, O. Occupational asthma: etiologies and risk factors. Allergy Asthma Immunol. Res. 3, 157\u2013167 (2011).","journal-title":"Allergy Asthma Immunol. Res."},{"key":"2853_CR124","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1067\/mai.2002.122157","volume":"109","author":"AH Liu","year":"2002","unstructured":"Liu, A. H. Endotoxin exposure in allergy and asthma: reconciling a paradox. J. Allergy Clin. Immunol. 109, 379\u2013392 (2002).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR125","doi-asserted-by":"publisher","first-page":"E465","DOI":"10.1503\/cmaj.241506","volume":"197","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. Impact of the 2023 wildfire smoke episodes in Ontario, Canada, on asthma and other health outcomes: an interrupted time-series analysis. CMAJ 197, E465\u2013E477 (2025).","journal-title":"CMAJ"},{"key":"2853_CR126","first-page":"806","volume":"16","author":"G D\u2019Amato","year":"2021","unstructured":"D\u2019Amato, G. et al. Thunderstorm allergy and asthma: state of the art. Multidiscip. Respir. Med. 16, 806 (2021).","journal-title":"Multidiscip. Respir. Med."},{"key":"2853_CR127","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jaip.2025.04.001","volume":"13","author":"F Thien","year":"2025","unstructured":"Thien, F., Davies, J. M., Douglass, J. A. & Hew, M. Thunderstorm asthma: current perspectives and emerging trends. J. Allergy Clin. Immunol. Pract. 13, 1273\u20131280 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR128","doi-asserted-by":"publisher","first-page":"e13780","DOI":"10.1111\/pai.13780","volume":"33","author":"N Hernandez-Pacheco","year":"2022","unstructured":"Hernandez-Pacheco, N., Kere, M. & Melen, E. Gene-environment interactions in childhood asthma revisited; expanding the interaction concept. Pediatr. Allergy Immunol. 33, e13780 (2022).","journal-title":"Pediatr. Allergy Immunol."},{"key":"2853_CR129","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1164\/rccm.202305-0934OC","volume":"209","author":"CA Jakwerth","year":"2024","unstructured":"Jakwerth, C. A. et al. 17q21 variants disturb mucosal host defense in childhood asthma. Am. J. Respir. Crit. Care Med. 209, 947\u2013959 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR130","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJMoa1211592","volume":"368","author":"M Caliskan","year":"2013","unstructured":"Caliskan, M. et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N. Engl. J. Med. 368, 1398\u20131407 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR131","doi-asserted-by":"publisher","first-page":"256ra134","DOI":"10.1126\/scitranslmed.3009124","volume":"6","author":"J Beale","year":"2014","unstructured":"Beale, J. et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci. Transl. Med. 6, 256ra134 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2853_CR132","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1513\/pats.200909-097RM","volume":"7","author":"I Romieu","year":"2010","unstructured":"Romieu, I., Moreno-Macias, H. & London, S. J. Gene by environment interaction and ambient air pollution. Proc. Am. Thorac. Soc. 7, 116\u2013122 (2010).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"2853_CR133","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1183\/09031936.06.00114905","volume":"28","author":"I Romieu","year":"2006","unstructured":"Romieu, I. et al. GSTM1 and GSTP1 and respiratory health in asthmatic children exposed to ozone. Eur. Respir. J. 28, 953\u2013959 (2006).","journal-title":"Eur. Respir. J."},{"key":"2853_CR134","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.freeradbiomed.2020.01.181","volume":"151","author":"E Fuertes","year":"2020","unstructured":"Fuertes, E., van der Plaat, D. A. & Minelli, C. Antioxidant genes and susceptibility to air pollution for respiratory and cardiovascular health. Free Radic. Biol. Med. 151, 88\u201398 (2020).","journal-title":"Free Radic. Biol. Med."},{"key":"2853_CR135","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/ajim.22012","volume":"55","author":"P Reddy","year":"2012","unstructured":"Reddy, P. et al. GSTM1 and GSTP1 gene variants and the effect of air pollutants on lung function measures in South African children. Am. J. Ind. Med. 55, 1078\u20131086 (2012).","journal-title":"Am. J. Ind. Med."},{"key":"2853_CR136","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1513\/pats.200702-035AW","volume":"4","author":"FD Martinez","year":"2007","unstructured":"Martinez, F. D. CD14, endotoxin, and asthma risk: actions and interactions. Proc. Am. Thorac. Soc. 4, 221\u2013225 (2007).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"2853_CR137","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jaci.2007.07.034","volume":"120","author":"C Bieli","year":"2007","unstructured":"Bieli, C. et al. A polymorphism in CD14 modifies the effect of farm milk consumption on allergic diseases and CD14 gene expression. J. Allergy Clin. Immunol. 120, 1308\u20131315 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR138","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jaip.2019.11.017","volume":"8","author":"T Brick","year":"2020","unstructured":"Brick, T. et al. The Beneficial Effect of Farm Milk Consumption on Asthma, Allergies, and Infections: From Meta-Analysis of Evidence to Clinical Trial. J. Allergy Clin. Immunol. Pract. 8, 878\u2013889.e873 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR139","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaci.2023.10.003","volume":"153","author":"ST Weiss","year":"2024","unstructured":"Weiss, S. T. et al. Prenatal vitamin D supplementation to prevent childhood asthma: 15-year results from the Vitamin D Antenatal Asthma Reduction Trial (VDAART). J. Allergy Clin. Immunol. 153, 378\u2013388 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR140","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/pai.13453","volume":"32","author":"N Brustad","year":"2021","unstructured":"Brustad, N. et al. High-dose vitamin D during pregnancy and pathway gene polymorphisms in prevention of offspring persistent wheeze. Pediatr. Allergy Immunol. 32, 679\u2013689 (2021).","journal-title":"Pediatr. Allergy Immunol."},{"key":"2853_CR141","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1096\/fsb2fj000432fje","volume":"15","author":"K Ito","year":"2001","unstructured":"Ito, K. et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 15, 1110\u20131112 (2001).","journal-title":"FASEB J."},{"key":"2853_CR142","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3892\/etm.2012.809","volume":"5","author":"M Panek","year":"2013","unstructured":"Panek, M. et al. Effect of glucocorticoid receptor gene polymorphisms on asthma phenotypes. Exp. Ther. Med. 5, 572\u2013580 (2013).","journal-title":"Exp. Ther. Med."},{"key":"2853_CR143","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaci.2023.09.004","volume":"153","author":"AM Zhang","year":"2024","unstructured":"Zhang, A. M., Banzon, T. M. & Phipatanakul, W. The spectrum of environmental disparities in asthma. J. Allergy Clin. Immunol. 153, 398\u2013400 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08469-7","volume":"10","author":"M Daya","year":"2019","unstructured":"Daya, M. et al. Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations. Nat. Commun. 10, 880 (2019).","journal-title":"Nat. Commun."},{"key":"2853_CR145","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/ng.888","volume":"43","author":"DG Torgerson","year":"2011","unstructured":"Torgerson, D. G. et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat. Genet. 43, 887\u2013892 (2011).","journal-title":"Nat. Genet."},{"key":"2853_CR146","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1164\/rccm.202405-1031LE","volume":"210","author":"J Ou","year":"2024","unstructured":"Ou, J., Yuan, Y., Fu, X. & Sun, Y. Beyond air pollution: addressing multifactorial contributors to asthma disparities in black and Latinx populations. Am. J. Respir. Crit. Care Med. 210, 696\u2013697 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR147","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1164\/rccm.201501-0037OC","volume":"192","author":"JM Brehm","year":"2015","unstructured":"Brehm, J. M. et al. Stress and bronchodilator response in children with asthma. Am. J. Respir. Crit. Care Med. 192, 47\u201356 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR148","doi-asserted-by":"publisher","first-page":"941944","DOI":"10.3389\/fmed.2022.941944","volume":"9","author":"Q Hui","year":"2022","unstructured":"Hui, Q. et al. Genetically high angiotensin-converting enzyme concentrations causally increase asthma risk: a meta-analysis using Mendelian randomization. Front. Med. 9, 941944 (2022).","journal-title":"Front. Med."},{"key":"2853_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100591","volume":"4","author":"AA Motsinger-Reif","year":"2024","unstructured":"Motsinger-Reif, A. A. et al. Gene-environment interactions within a precision environmental health framework. Cell Genom. 4, 100591 (2024).","journal-title":"Cell Genom."},{"key":"2853_CR150","doi-asserted-by":"crossref","unstructured":"Mohammadi, T., Sadatsafavi, M. & Carlsten, C. The economics of precision health: preventing air pollution-induced exacerbation in asthma. ERJ Open Res. 7, 00790\u20132020 (2021).","DOI":"10.1183\/23120541.00790-2020"},{"key":"2853_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37626-2","volume":"14","author":"A Baccarelli","year":"2023","unstructured":"Baccarelli, A., Dolinoy, D. C. & Walker, C. L. A precision environmental health approach to prevention of human disease. Nat. Commun. 14, 2449 (2023).","journal-title":"Nat. Commun."},{"key":"2853_CR152","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaci.2009.12.014","volume":"125","author":"S Kazani","year":"2010","unstructured":"Kazani, S., Wechsler, M. E. & Israel, E. The role of pharmacogenomics in improving the management of asthma. J. Allergy Clin. Immunol. 125, 295\u2013302 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR153","doi-asserted-by":"crossref","unstructured":"Koppelman, G. H. et al. Genetic and environmental risk factors for asthma: towards prevention. Lancet Respir Med. 13, 1011\u20131025 (2025).","DOI":"10.1016\/S2213-2600(25)00256-5"},{"key":"2853_CR154","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/japplphysiol.01111.2009","volume":"109","author":"SD Amin","year":"2010","unstructured":"Amin, S. D., Majumdar, A., Frey, U. & Suki, B. Modeling the dynamics of airway constriction: effects of agonist transport and binding. J. Appl. Physiol. 109, 553\u2013563 (2010).","journal-title":"J. Appl. Physiol."},{"key":"2853_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201658","volume":"14","author":"KL Raby","year":"2023","unstructured":"Raby, K. L. et al. Mechanisms of airway epithelial injury and abnormal repair in asthma and COPD. Front. Immunol. 14, 1201658 (2023).","journal-title":"Front. Immunol."},{"key":"2853_CR156","doi-asserted-by":"publisher","first-page":"975914","DOI":"10.3389\/fimmu.2022.975914","volume":"13","author":"M Duchesne","year":"2022","unstructured":"Duchesne, M., Okoye, I. & Lacy, P. Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response. Front. Immunol. 13, 975914 (2022).","journal-title":"Front. Immunol."},{"key":"2853_CR157","doi-asserted-by":"publisher","first-page":"1478624","DOI":"10.3389\/fimmu.2024.1478624","volume":"15","author":"C Xie","year":"2024","unstructured":"Xie, C. et al. Immunologic aspects of asthma: from molecular mechanisms to disease pathophysiology and clinical translation. Front. Immunol. 15, 1478624 (2024).","journal-title":"Front. Immunol."},{"key":"2853_CR158","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/thorax.58.9.772","volume":"58","author":"NJ Kenyon","year":"2003","unstructured":"Kenyon, N. J., Ward, R. W., McGrew, G. & Last, J. A. TGF-beta1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax 58, 772\u2013777 (2003).","journal-title":"Thorax"},{"key":"2853_CR159","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2147\/JAA.S360381","volume":"15","author":"LL Xiang","year":"2022","unstructured":"Xiang, L. L. et al. IL-13 regulates orai1 expression in human bronchial smooth muscle cells and airway remodeling in asthma mice model via LncRNA H19. J. Asthma Allergy 15, 1245\u20131261 (2022).","journal-title":"J. Asthma Allergy"},{"key":"2853_CR160","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.jaci.2021.03.035","volume":"147","author":"B Camoretti-Mercado","year":"2021","unstructured":"Camoretti-Mercado, B. & Lockey, R. F. Airway smooth muscle pathophysiology in asthma. J. Allergy Clin. Immunol. 147, 1983\u20131995 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR161","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1165\/rcmb.2006-0180OC","volume":"36","author":"G Zhen","year":"2007","unstructured":"Zhen, G. et al. IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. Am. J. Respir. Cell Mol. Biol. 36, 244\u2013253 (2007).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR162","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1172\/JCI84910","volume":"126","author":"LR Bonser","year":"2016","unstructured":"Bonser, L. R., Zlock, L., Finkbeiner, W. & Erle, D. J. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J. Clin. Investig. 126, 2367\u20132371 (2016).","journal-title":"J. Clin. Investig."},{"key":"2853_CR163","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1513\/AnnalsATS.201807-485AW","volume":"15","author":"EM Dunican","year":"2018","unstructured":"Dunican, E. M., Watchorn, D. C. & Fahy, J. V. Autopsy and imaging studies of mucus in asthma. Lessons learned about disease mechanisms and the role of mucus in airflow obstruction. Ann. Am. Thorac. Soc. 15, S184\u2013S191 (2018).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2853_CR164","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaip.2025.01.010","volume":"13","author":"J Gotschke","year":"2025","unstructured":"Gotschke, J. et al. Mucus plug score predicts clinical and pulmonary function response to biologic therapy in patients with severe asthma. J. Allergy Clin. Immunol. Pract. 13, 1110\u20131122.e1111 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100566","volume":"4","author":"N Tanabe","year":"2025","unstructured":"Tanabe, N. et al. Clinical and pathophysiological roles of lower lobe-dominant mucus plugs on computed tomography in patients with asthma with and without bronchiectasis. J. Allergy Clin. Immunol. Glob. 4, 100566 (2025).","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"2853_CR166","doi-asserted-by":"publisher","first-page":"EVIDoa2300135","DOI":"10.1056\/EVIDoa2300135","volume":"2","author":"LH Nordenmark","year":"2023","unstructured":"Nordenmark, L. H. et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2, EVIDoa2300135 (2023).","journal-title":"NEJM Evid."},{"key":"2853_CR167","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1164\/rccm.200507-1105OC","volume":"173","author":"BN Feltis","year":"2006","unstructured":"Feltis, B. N. et al. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am. J. Respir. Crit. Care Med. 173, 1201\u20131207 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR168","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1164\/ajrccm.159.3.9712144","volume":"159","author":"M Haraguchi","year":"1999","unstructured":"Haraguchi, M., Shimura, S. & Shirato, K. Morphometric analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. Am. J. Respir. Crit. Care Med. 159, 1005\u20131013 (1999).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR169","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.pccm.2023.07.002","volume":"1","author":"D Toumpanakis","year":"2023","unstructured":"Toumpanakis, D. & Usmani, O. S. Small airways in asthma: pathophysiology, identification and management. Chin. Med. J. Pulm. Crit. Care Med. 1, 171\u2013180 (2023).","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"2853_CR170","doi-asserted-by":"publisher","first-page":"107532","DOI":"10.1016\/j.rmed.2024.107532","volume":"222","author":"A Siora","year":"2024","unstructured":"Siora, A. et al. Small airways in asthma: from inflammation and pathophysiology to treatment response. Respir. Med. 222, 107532 (2024).","journal-title":"Respir. Med."},{"key":"2853_CR171","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2012.08.044","volume":"131","author":"R O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly, R. et al. Increased airway smooth muscle in preschool wheezers who have asthma at school age. J. Allergy Clin. Immunol. 131, 1024\u20131032 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR172","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaci.2019.01.014","volume":"144","author":"AJ Bell","year":"2019","unstructured":"Bell, A. J. et al. Functional CT imaging for identification of the spatial determinants of small-airways disease in adults with asthma. J. Allergy Clin. Immunol. 144, 83\u201393 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR173","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/mp.17009","volume":"51","author":"K Qing","year":"2024","unstructured":"Qing, K. et al. Pulmonary MRI with hyperpolarized xenon-129 demonstrates novel alterations in gas transfer across the air-blood barrier in asthma. Med. Phys. 51, 2413\u20132423 (2024).","journal-title":"Med. Phys."},{"key":"2853_CR174","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1148\/radiol.2021204616","volume":"303","author":"DG Mummy","year":"2022","unstructured":"Mummy, D. G. et al. Mucus plugs in asthma at CT associated with regional ventilation defects at (3)He MRI. Radiology 303, 184\u2013190 (2022).","journal-title":"Radiology"},{"key":"2853_CR175","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000531205","volume":"102","author":"R Pisi","year":"2023","unstructured":"Pisi, R. et al. Detection of small airway dysfunction in asthmatic patients by spirometry and impulse oscillometry system. Respiration 102, 487\u2013494 (2023).","journal-title":"Respiration"},{"key":"2853_CR176","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41590-025-02212-9","volume":"26","author":"BN Lambrecht","year":"2025","unstructured":"Lambrecht, B. N., Ahmed, E. & Hammad, H. The immunology of asthma. Nat. Immunol. 26, 1233\u20131245 (2025).","journal-title":"Nat. Immunol."},{"key":"2853_CR177","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jaci.2012.02.028","volume":"129","author":"MA Gill","year":"2012","unstructured":"Gill, M. A. The role of dendritic cells in asthma. J. Allergy Clin. Immunol. 129, 889\u2013901 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR178","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20051135","volume":"202","author":"T Ito","year":"2005","unstructured":"Ito, T. et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202, 1213\u20131223 (2005).","journal-title":"J. Exp. Med."},{"key":"2853_CR179","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1084\/jem.20070406","volume":"204","author":"YH Wang","year":"2007","unstructured":"Wang, Y. H. et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J. Exp. Med. 204, 1837\u20131847 (2007).","journal-title":"J. Exp. Med."},{"key":"2853_CR180","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1164\/rccm.201509-1751OC","volume":"193","author":"D Tworek","year":"2016","unstructured":"Tworek, D. et al. IL-25 receptor expression on airway dendritic cells after allergen challenge in subjects with asthma. Am. J. Respir. Crit. Care Med. 193, 957\u2013964 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR181","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","volume":"188","author":"WW Busse","year":"2013","unstructured":"Busse, W. W. et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 188, 1294\u20131302 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR182","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","volume":"10","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential. Signal Transduct. Target Ther. 10, 345 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2853_CR183","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/ACI.0000000000000887","volume":"23","author":"H Harb","year":"2023","unstructured":"Harb, H. & Chatila, T. A. Regulatory T-cells in asthma. Curr. Opin. Allergy Clin. Immunol. 23, 151\u2013157 (2023).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"2853_CR184","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaci.2024.10.033","volume":"155","author":"M Rosenzwajg","year":"2025","unstructured":"Rosenzwajg, M. et al. Low-dose IL-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial. J. Allergy Clin. Immunol. 155, 650\u2013655 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR185","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s12276-023-01021-0","volume":"55","author":"CL Thio","year":"2023","unstructured":"Thio, C. L. & Chang, Y. J. The modulation of pulmonary group 2 innate lymphoid cell function in asthma: from inflammatory mediators to environmental and metabolic factors. Exp. Mol. Med. 55, 1872\u20131884 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2853_CR186","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature24029","volume":"549","author":"A Wallrapp","year":"2017","unstructured":"Wallrapp, A. et al. The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation. Nature 549, 351\u2013356 (2017).","journal-title":"Nature"},{"key":"2853_CR187","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1164\/rccm.202311-2164OC","volume":"210","author":"X Ju","year":"2024","unstructured":"Ju, X. et al. Neuromedin-U mediates rapid activation of airway group 2 innate lymphoid cells in mild asthma. Am. J. Respir. Crit. Care Med. 210, 755\u2013765 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR188","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado6649","volume":"17","author":"X Ju","year":"2025","unstructured":"Ju, X. et al. A population of c-kit(+) IL-17A(+) ILC2s in sputum from individuals with severe asthma supports ILC2 to ILC3 trans-differentiation. Sci. Transl. Med. 17, eado6649 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2853_CR189","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2213-2600(25)00174-2","volume":"13","author":"M Lommatzsch","year":"2025","unstructured":"Lommatzsch, M. et al. Eosinophils in asthma phenotypes: perpetrators or guilty by association? Lancet Respir. Med. 13, 943\u2013950 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR190","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S2213-2600(24)00380-1","volume":"13","author":"REK Russell","year":"2025","unstructured":"Russell, R. E. K. Management and mechanisms of eosinophil action in asthma: mind the gap? Lancet Respir. Med. 13, 190\u2013191 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR191","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMoa012705","volume":"346","author":"CE Brightling","year":"2002","unstructured":"Brightling, C. E. et al. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 346, 1699\u20131705 (2002).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR192","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jaci.2013.10.056","volume":"133","author":"L Xue","year":"2014","unstructured":"Xue, L. et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J. Allergy Clin. Immunol. 133, 1184\u20131194 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR193","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","volume":"9","author":"CE Brightling","year":"2021","unstructured":"Brightling, C. E. et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir. Med. 9, 43\u201356 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR194","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12931-024-02923-x","volume":"25","author":"W Gu","year":"2024","unstructured":"Gu, W. et al. The role of extracellular traps released by neutrophils, eosinophils, and macrophages in asthma. Respir. Res 25, 290 (2024).","journal-title":"Respir. Res"},{"key":"2853_CR195","doi-asserted-by":"publisher","first-page":"851940","DOI":"10.3389\/fphar.2022.851940","volume":"13","author":"C Pelaia","year":"2022","unstructured":"Pelaia, C. et al. Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets. Front Pharm. 13, 851940 (2022).","journal-title":"Front Pharm."},{"key":"2853_CR196","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1164\/rccm.202003-0729LE","volume":"202","author":"AM Moran","year":"2020","unstructured":"Moran, A. M. et al. Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma. Am. J. Respir. Crit. Care Med. 202, 1314\u20131316 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-024-09012-3","volume":"68","author":"M Berkinbayeva","year":"2024","unstructured":"Berkinbayeva, M., Gu, W., Chen, Z. & Gao, P. Group 3 innate lymphoid cells: a potential therapeutic target for steroid resistant asthma. Clin. Rev. Allergy Immunol. 68, 1 (2024).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2853_CR198","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/01902148.2016.1190796","volume":"42","author":"K Honda","year":"2016","unstructured":"Honda, K. et al. IL-17A synergistically stimulates TNF-alpha-induced IL-8 production in human airway epithelial cells: A potential role in amplifying airway inflammation. Exp. Lung Res. 42, 205\u2013216 (2016).","journal-title":"Exp. Lung Res."},{"key":"2853_CR199","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1084\/jem.20061401","volume":"203","author":"S Schnyder-Candrian","year":"2006","unstructured":"Schnyder-Candrian, S. et al. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 203, 2715\u20132725 (2006).","journal-title":"J. Exp. Med."},{"key":"2853_CR200","doi-asserted-by":"publisher","first-page":"301ra129","DOI":"10.1126\/scitranslmed.aab3142","volume":"7","author":"DF Choy","year":"2015","unstructured":"Choy, D. F. et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci. Transl. Med. 7, 301ra129 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2853_CR201","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1183\/09031936.00063510","volume":"37","author":"ST Holgate","year":"2011","unstructured":"Holgate, S. T. et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur. Respir. J. 37, 1352\u20131359 (2011).","journal-title":"Eur. Respir. J."},{"key":"2853_CR202","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","volume":"179","author":"SE Wenzel","year":"2009","unstructured":"Wenzel, S. E. et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med. 179, 549\u2013558 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR203","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1165\/rcmb.2010-0027TR","volume":"44","author":"R Halwani","year":"2011","unstructured":"Halwani, R., Al-Muhsen, S., Al-Jahdali, H. & Hamid, Q. Role of transforming growth factor-beta in airway remodeling in asthma. Am. J. Respir. Cell Mol. Biol. 44, 127\u2013133 (2011).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR204","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jaci.2006.04.010","volume":"118","author":"P Montuschi","year":"2006","unstructured":"Montuschi, P. et al. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J. Allergy Clin. Immunol. 118, 347\u2013353 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR205","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12931-021-01852-3","volume":"22","author":"S Carstensen","year":"2021","unstructured":"Carstensen, S. et al. Prostaglandin D(2) metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP(2) receptor. Respir. Res. 22, 262 (2021).","journal-title":"Respir. Res."},{"key":"2853_CR206","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrd2266","volume":"6","author":"R Pettipher","year":"2007","unstructured":"Pettipher, R., Hansel, T. T. & Armer, R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 6, 313\u2013325 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2853_CR207","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1164\/rccm.200801-061OC","volume":"178","author":"A Planaguma","year":"2008","unstructured":"Planaguma, A. et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 178, 574\u2013582 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR208","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1096\/fj.07-8653com","volume":"21","author":"BD Levy","year":"2007","unstructured":"Levy, B. D. et al. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J. 21, 3877\u20133884 (2007).","journal-title":"FASEB J."},{"key":"2853_CR209","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3892\/etm.2017.4787","volume":"14","author":"X Kong","year":"2017","unstructured":"Kong, X., Wu, S. H., Zhang, L. & Chen, X. Q. Pilot application of lipoxin A(4) analog and lipoxin A(4) receptor agonist in asthmatic children with acute episodes. Exp. Ther. Med. 14, 2284\u20132290 (2017).","journal-title":"Exp. Ther. Med."},{"key":"2853_CR210","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-019-0079-0","volume":"4","author":"SS Athari","year":"2019","unstructured":"Athari, S. S. Targeting cell signaling in allergic asthma. Signal. Transduct. Target Ther. 4, 45 (2019).","journal-title":"Signal. Transduct. Target Ther."},{"key":"2853_CR211","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1172\/JCI0215786","volume":"109","author":"AB Pernis","year":"2002","unstructured":"Pernis, A. B. & Rothman, P. B. JAK-STAT signaling in asthma. J. Clin. Invest 109, 1279\u20131283 (2002).","journal-title":"J. Clin. Invest"},{"key":"2853_CR212","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1067\/mai.2000.107604","volume":"105","author":"H Jiang","year":"2000","unstructured":"Jiang, H., Harris, M. B. & Rothman, P. IL-4\/IL-13 signaling beyond JAK\/STAT. J. Allergy Clin. Immunol. 105, 1063\u20131070 (2000).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR213","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0394632015623794","volume":"29","author":"A Antczak","year":"2016","unstructured":"Antczak, A. et al. Analysis of changes in expression of IL-4\/IL-13\/STAT6 pathway and correlation with the selected clinical parameters in patients with atopic asthma. Int. J. Immunopathol. Pharm. 29, 195\u2013204 (2016).","journal-title":"Int. J. Immunopathol. Pharm."},{"key":"2853_CR214","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1046\/j.1365-2222.1999.00405.x","volume":"29","author":"S Miyata","year":"1999","unstructured":"Miyata, S. et al. STAT6 deficiency in a mouse model of allergen-induced airways inflammation abolishes eosinophilia but induces infiltration of CD8+ T cells. Clin. Exp. Allergy 29, 114\u2013123 (1999).","journal-title":"Clin. Exp. Allergy"},{"key":"2853_CR215","doi-asserted-by":"publisher","first-page":"19455","DOI":"10.1073\/pnas.1008271107","volume":"107","author":"Y Rochman","year":"2010","unstructured":"Rochman, Y. et al. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc. Natl. Acad. Sci. USA 107, 19455\u201319460 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2853_CR216","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jaci.2021.08.013","volume":"148","author":"SN Georas","year":"2021","unstructured":"Georas, S. N., Donohue, P., Connolly, M. & Wechsler, M. E. JAK inhibitors for asthma. J. Allergy Clin. Immunol. 148, 953\u2013963 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR217","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2147\/DDDT.S354291","volume":"16","author":"M Nilsson","year":"2022","unstructured":"Nilsson, M. et al. Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of asthma. Drug Des. Devel Ther. 16, 2901\u20132917 (2022).","journal-title":"Drug Des. Devel Ther."},{"key":"2853_CR218","doi-asserted-by":"publisher","first-page":"AB98","DOI":"10.1016\/j.jaci.2023.11.323","volume":"153","author":"TJ Jensen","year":"2024","unstructured":"Jensen, T. J. et al. AZD4604, an inhaled, selective JAK1 inhibitor reduces fractional exhaled nitric oxide in patients with mild asthma; a randomized, single-blind phase 1 study. J. Allergy Clin. Immun. 153, AB98 (2024).","journal-title":"J. Allergy Clin. Immun."},{"key":"2853_CR219","doi-asserted-by":"publisher","first-page":"17023\u2013","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal Transduct. Target Ther. 2, 17023\u2013 (2017).","journal-title":"Signal Transduct. Target Ther."},{"key":"2853_CR220","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44466-025-00014-0","volume":"1","author":"A Hoffmann","year":"2025","unstructured":"Hoffmann, A., Cheng, G. & Baltimore, D. NF-\u03baB: master regulator of cellular responses in health and disease. Immun. Inflamm. 1, 2 (2025).","journal-title":"Immun. Inflamm."},{"key":"2853_CR221","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jaci.2007.01.015","volume":"119","author":"PJ Barnes","year":"2007","unstructured":"Barnes, P. J. New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol. 119, 1055\u20131062 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR222","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","volume":"131","author":"PJ Barnes","year":"2013","unstructured":"Barnes, P. J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 131, 636\u2013645 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR223","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00109-011-0748-0","volume":"89","author":"A Salminen","year":"2011","unstructured":"Salminen, A., Hyttinen, J. M. & Kaarniranta, K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. 89, 667\u2013676 (2011).","journal-title":"J. Mol. Med."},{"key":"2853_CR224","doi-asserted-by":"crossref","unstructured":"Choi, H. M., Doss, H. M. & Kim, K. S. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int. J. Mol. Sci. 21, 1219 (2020).","DOI":"10.3390\/ijms21041219"},{"key":"2853_CR225","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2222.2010.03658.x","volume":"41","author":"R Alam","year":"2011","unstructured":"Alam, R. & Gorska, M. M. Mitogen-activated protein kinase signalling and ERK1\/2 bistability in asthma. Clin. Exp. Allergy 41, 149\u2013159 (2011).","journal-title":"Clin. Exp. Allergy"},{"key":"2853_CR226","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jaci.2008.02.004","volume":"121","author":"W Liu","year":"2008","unstructured":"Liu, W. et al. Cell-specific activation profile of extracellular signal-regulated kinase 1\/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J. Allergy Clin. Immunol. 121, 893\u2013902.e892 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR227","doi-asserted-by":"publisher","first-page":"10833","DOI":"10.1096\/fj.201900680R","volume":"33","author":"AE Defnet","year":"2019","unstructured":"Defnet, A. E. et al. Effects of ATP-competitive and function-selective ERK inhibitors on airway smooth muscle cell proliferation. FASEB J. 33, 10833\u201310843 (2019).","journal-title":"FASEB J."},{"key":"2853_CR228","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00071309","volume":"35","author":"P Bhavsar","year":"2010","unstructured":"Bhavsar, P. et al. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur. Respir. J. 35, 750\u2013756 (2010).","journal-title":"Eur. Respir. J."},{"key":"2853_CR229","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/17476348.2020.1735365","volume":"14","author":"C Pelaia","year":"2020","unstructured":"Pelaia, C. et al. Clinical relevance of understanding mitogen-activated protein kinases involved in asthma. Expert Rev. Respir. Med. 14, 501\u2013510 (2020).","journal-title":"Expert Rev. Respir. Med."},{"key":"2853_CR230","doi-asserted-by":"crossref","unstructured":"Jeong, J. S., Kim, J. S., Kim, S. R. & Lee, Y. C. Defining bronchial asthma with phosphoinositide 3-kinase delta activation: towards endotype-driven management. Int. J. Mol. Sci. 20, 3525 (2019).","DOI":"10.3390\/ijms20143525"},{"key":"2853_CR231","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/jpet.118.249516","volume":"367","author":"S Khindri","year":"2018","unstructured":"Khindri, S. et al. A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma. J. Pharm. Exp. Ther. 367, 405\u2013413 (2018).","journal-title":"J. Pharm. Exp. Ther."},{"key":"2853_CR232","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1183\/09031936.00105013","volume":"43","author":"JL Simpson","year":"2014","unstructured":"Simpson, J. L. et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur. Respir. J. 43, 1067\u20131076 (2014).","journal-title":"Eur. Respir. J."},{"key":"2853_CR233","doi-asserted-by":"crossref","unstructured":"Liu, T., Woodruff, P. G. & Zhou, X. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. Eur. Respir. J. 64, 2300826 (2024).","DOI":"10.1183\/13993003.00826-2023"},{"key":"2853_CR234","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1172\/JCI128310","volume":"130","author":"I Tindemans","year":"2020","unstructured":"Tindemans, I. et al. Notch signaling licenses allergic airway inflammation by promoting Th2 cell lymph node egress. J. Clin. Investig. 130, 3576\u20133591 (2020).","journal-title":"J. Clin. Investig."},{"key":"2853_CR235","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1165\/rcmb.2019-0069OC","volume":"62","author":"AT Reid","year":"2020","unstructured":"Reid, A. T. et al. Blocking Notch3 signaling abolishes MUC5AC production in airway epithelial cells from individuals with asthma. Am. J. Respir. Cell Mol. Biol. 62, 513\u2013523 (2020).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR236","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1134","volume":"9","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. RhoA\/Rho-kinases in asthma: from pathogenesis to therapeutic targets. Clin. Transl. Immunol. 9, e01134 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"2853_CR237","doi-asserted-by":"crossref","unstructured":"Wang, L., Chitano, P., Pare, P. D. & Seow, C. Y. Upregulation of smooth muscle Rho-kinase protein expression in human asthma. Eur. Respir. J. 55, 1901785 (2020).","DOI":"10.1183\/13993003.01785-2019"},{"key":"2853_CR238","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2401251121","volume":"121","author":"U Ngo","year":"2024","unstructured":"Ngo, U. et al. IL-13 and IL-17A activate beta1 integrin through an NF-kB\/Rho kinase\/PIP5K1gamma pathway to enhance force transmission in airway smooth muscle. Proc. Natl. Acad. Sci. USA 121, e2401251121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2853_CR239","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cyto.2011.10.014","volume":"57","author":"H Matsumoto","year":"2012","unstructured":"Matsumoto, H. et al. Interleukin-13 enhanced Ca2+ oscillations in airway smooth muscle cells. Cytokine 57, 19\u201324 (2012).","journal-title":"Cytokine"},{"key":"2853_CR240","doi-asserted-by":"publisher","first-page":"1211949","DOI":"10.3389\/falgy.2023.1211949","volume":"4","author":"AH Rovsing","year":"2023","unstructured":"Rovsing, A. H., Savran, O. & Ulrik, C. S. Magnesium sulfate treatment for acute severe asthma in adults-a systematic review and meta-analysis. Front. Allergy 4, 1211949 (2023).","journal-title":"Front. Allergy"},{"key":"2853_CR241","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.abb.2019.01.002","volume":"663","author":"S Pan","year":"2019","unstructured":"Pan, S., Conaway, S. Jr. & Deshpande, D. A. Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases. Arch. Biochem. Biophys. 663, 109\u2013119 (2019).","journal-title":"Arch. Biochem. Biophys."},{"key":"2853_CR242","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1165\/rcmb.2013-0519OC","volume":"52","author":"OA Jaffer","year":"2015","unstructured":"Jaffer, O. A. et al. Mitochondrial-targeted antioxidant therapy decreases transforming growth factor-beta-mediated collagen production in a murine asthma model. Am. J. Respir. Cell Mol. Biol. 52, 106\u2013115 (2015).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR243","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.780148","volume":"13","author":"W Ma","year":"2022","unstructured":"Ma, W. et al. Metformin ameliorates inflammation and airway remodeling of experimental allergic asthma in mice by restoring AMPKalpha activity. Front. Pharm. 13, 780148 (2022).","journal-title":"Front. Pharm."},{"key":"2853_CR244","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","volume":"185","author":"B Lee","year":"2025","unstructured":"Lee, B. et al. Antidiabetic medication and asthma attacks. JAMA Intern Med. 185, 16\u201325 (2025).","journal-title":"JAMA Intern Med."},{"key":"2853_CR245","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12931-015-0253-z","volume":"16","author":"RH Brown","year":"2015","unstructured":"Brown, R. H. et al. Sulforaphane improves the bronchoprotective response in asthmatics through Nrf2-mediated gene pathways. Respir. Res. 16, 106 (2015).","journal-title":"Respir. Res."},{"key":"2853_CR246","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12931-016-0406-8","volume":"17","author":"CG Duran","year":"2016","unstructured":"Duran, C. G. et al. A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation. Respir. Res. 17, 89 (2016).","journal-title":"Respir. Res."},{"key":"2853_CR247","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.immuni.2015.08.017","volume":"43","author":"JP Ray","year":"2015","unstructured":"Ray, J. P. et al. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity 43, 690\u2013702 (2015).","journal-title":"Immunity"},{"key":"2853_CR248","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/jcmm.16269","volume":"25","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma. J. Cell Mol. Med. 25, 2279\u20132284 (2021).","journal-title":"J. Cell Mol. Med."},{"key":"2853_CR249","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1067\/mai.2000.107038","volume":"106","author":"H Kankaanranta","year":"2000","unstructured":"Kankaanranta, H. et al. Delayed eosinophil apoptosis in asthma. J. Allergy Clin. Immunol. 106, 77\u201383 (2000).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR250","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/ppul.26079","volume":"57","author":"ES Ahmad","year":"2022","unstructured":"Ahmad, E. S. et al. Autophagy-related 5 gene mRNA expression and ATG5 rs510432 polymorphism in children with bronchial asthma. Pediatr. Pulmonol. 57, 2659\u20132664 (2022).","journal-title":"Pediatr. Pulmonol."},{"key":"2853_CR251","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12931-024-02702-8","volume":"25","author":"W Wu","year":"2024","unstructured":"Wu, W., Li, J., Chen, S. & Ouyang, S. The airway neuro-immune axis as a therapeutic target in allergic airway diseases. Respir. Res. 25, 83 (2024).","journal-title":"Respir. Res."},{"key":"2853_CR252","doi-asserted-by":"crossref","unstructured":"Koster, C. S. et al. Neuroplasticity and neuroimmune interactions with type 2 inflammation in asthma. Eur. Respir Rev. 35, 250159 (2026).","DOI":"10.1183\/16000617.0159-2025"},{"key":"2853_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13202","volume":"7","author":"L Galle-Treger","year":"2016","unstructured":"Galle-Treger, L. et al. Nicotinic acetylcholine receptor agonist attenuates ILC2-dependent airway hyperreactivity. Nat. Commun. 7, 13202 (2016).","journal-title":"Nat. Commun."},{"key":"2853_CR254","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1126\/science.aan4829","volume":"359","author":"S Moriyama","year":"2018","unstructured":"Moriyama, S. et al. beta(2)-adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses. Science 359, 1056\u20131061 (2018).","journal-title":"Science"},{"key":"2853_CR255","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bbi.2014.10.007","volume":"45","author":"K Kolmus","year":"2015","unstructured":"Kolmus, K., Tavernier, J. & Gerlo, S. beta2-Adrenergic receptors in immunity and inflammation: stressing NF-kappaB. Brain Behav. Immun. 45, 297\u2013310 (2015).","journal-title":"Brain Behav. Immun."},{"key":"2853_CR256","doi-asserted-by":"publisher","first-page":"135719","DOI":"10.1016\/j.neulet.2021.135719","volume":"748","author":"Q Gu","year":"2021","unstructured":"Gu, Q. & Lee, L. Y. TRP channels in airway sensory nerves. Neurosci. Lett. 748, 135719 (2021).","journal-title":"Neurosci. Lett."},{"key":"2853_CR257","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1152\/physiol.00026.2008","volume":"23","author":"BF Bessac","year":"2008","unstructured":"Bessac, B. F. & Jordt, S. E. Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control. Physiology 23, 360\u2013370 (2008).","journal-title":"Physiology"},{"key":"2853_CR258","doi-asserted-by":"publisher","first-page":"9099","DOI":"10.1073\/pnas.0900591106","volume":"106","author":"AI Caceres","year":"2009","unstructured":"Caceres, A. I. et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc. Natl. Acad. Sci. USA 106, 9099\u20139104 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2853_CR259","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106696","volume":"86","author":"M Li","year":"2020","unstructured":"Li, M. et al. The neuro-immune interaction in airway inflammation through TRPA1 expression in CD4+ T cells of asthmatic mice. Int. Immunopharmacol. 86, 106696 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2853_CR260","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41573-021-00268-4","volume":"21","author":"AP Koivisto","year":"2022","unstructured":"Koivisto, A. P., Belvisi, M. G., Gaudet, R. & Szallasi, A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat. Rev. Drug Discov. 21, 41\u201359 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2853_CR261","unstructured":"Balestrini, A. et al. A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. J. Exp. Med. 218, e20201637 (2021)."},{"key":"2853_CR262","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature23469","volume":"549","author":"V Cardoso","year":"2017","unstructured":"Cardoso, V. et al. Neuronal regulation of type 2 innate lymphoid cells via neuromedin U. Nature 549, 277\u2013281 (2017).","journal-title":"Nature"},{"key":"2853_CR263","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nature23676","volume":"549","author":"CSN Klose","year":"2017","unstructured":"Klose, C. S. N. et al. The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation. Nature 549, 282\u2013286 (2017).","journal-title":"Nature"},{"key":"2853_CR264","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1165\/rcmb.2022-0123OC","volume":"68","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Neuromedin U induces pulmonary ILC2 activation via the NMUR1 pathway during acute respiratory syncytial virus infection. Am. J. Respir. Cell Mol. Biol. 68, 256\u2013266 (2023).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR265","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66683-y","volume":"17","author":"D Wang","year":"2025","unstructured":"Wang, D. et al. mTORC1 signaling in group 2 innate lymphoid cells coordinates neuro-immune crosstalk in allergic lung inflammation. Nat. Commun. 17, 62 (2025).","journal-title":"Nat. Commun."},{"key":"2853_CR266","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41385-022-00543-6","volume":"15","author":"Y Ye","year":"2022","unstructured":"Ye, Y. et al. Neuromedin U promotes human type 2 immune responses. Mucosal Immunol. 15, 990\u2013999 (2022).","journal-title":"Mucosal Immunol."},{"key":"2853_CR267","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12931-019-1077-z","volume":"20","author":"L Long","year":"2019","unstructured":"Long, L. et al. Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough. Respir. Res. 20, 112 (2019).","journal-title":"Respir. Res."},{"key":"2853_CR268","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi, R. et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385, 1198\u20131205 (2015).","journal-title":"Lancet"},{"key":"2853_CR269","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey, L. P. et al. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 399, 909\u2013923 (2022).","journal-title":"Lancet"},{"key":"2853_CR270","doi-asserted-by":"publisher","first-page":"1240248","DOI":"10.3389\/fimmu.2023.1240248","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Brain response in asthma: the role of \u201clung-brain\u201d axis mediated by neuroimmune crosstalk. Front. Immunol. 14, 1240248 (2023).","journal-title":"Front. Immunol."},{"key":"2853_CR271","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-017-0554-8","volume":"18","author":"N Facciolongo","year":"2018","unstructured":"Facciolongo, N. et al. Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma. BMC Pulm. Med. 18, 29 (2018).","journal-title":"BMC Pulm. Med."},{"key":"2853_CR272","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1164\/rccm.200608-1186OC","volume":"175","author":"JD Boot","year":"2007","unstructured":"Boot, J. D. et al. Effect of an NK1\/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am. J. Respir. Crit. Care Med. 175, 450\u2013457 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR273","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1164\/ajrccm.153.6.8665034","volume":"153","author":"GF Joos","year":"1996","unstructured":"Joos, G. F., Van Schoor, J., Kips, J. C. & Pauwels, R. A. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics. Am. J. Respir. Crit. Care Med. 153, 1781\u20131784 (1996).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR274","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2466-11-41","volume":"11","author":"R Ramalho","year":"2011","unstructured":"Ramalho, R., Soares, R., Couto, N. & Moreira, A. Tachykinin receptors antagonism for asthma: a systematic review. BMC Pulm. Med. 11, 41 (2011).","journal-title":"BMC Pulm. Med."},{"key":"2853_CR275","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1398-9995.2012.02832.x","volume":"67","author":"I Agache","year":"2012","unstructured":"Agache, I., Akdis, C., Jutel, M. & Virchow, J. C. Untangling asthma phenotypes and endotypes. Allergy 67, 835\u2013846 (2012).","journal-title":"Allergy"},{"key":"2853_CR276","doi-asserted-by":"crossref","unstructured":"McDonald, V. M. et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J. 53, 1802058 (2019).","DOI":"10.1183\/13993003.02058-2018"},{"key":"2853_CR277","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaci.2025.03.008","volume":"156","author":"AL Fuhlbrigge","year":"2025","unstructured":"Fuhlbrigge, A. L. & Sharma, S. Unraveling the heterogeneity of asthma: decoding subtypes of asthma. J. Allergy Clin. Immunol. 156, 41\u201350 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR278","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ni.3244","volume":"16","author":"L Guo","year":"2015","unstructured":"Guo, L. et al. Innate immunological function of TH2 cells in vivo. Nat. Immunol. 16, 1051\u20131059 (2015).","journal-title":"Nat. Immunol."},{"key":"2853_CR279","doi-asserted-by":"crossref","unstructured":"Kyriakopoulos, C., Gogali, A., Bartziokas, K. & Kostikas, K. Identification and treatment of T2-low asthma in the era of biologics. ERJ Open Res. 7, 00309\u20132020 (2021).","DOI":"10.1183\/23120541.00309-2020"},{"key":"2853_CR280","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O\u2019Byrne","year":"2016","unstructured":"O\u2019Byrne, P. M. et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 4, 797\u2013806 (2016).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR281","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1165\/rcmb.2006-0419OC","volume":"37","author":"V Suresh","year":"2007","unstructured":"Suresh, V., Mih, J. D. & George, S. C. Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 37, 97\u2013104 (2007).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR282","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","volume":"154","author":"LB Bacharier","year":"2024","unstructured":"Bacharier, L. B. et al. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma. J. Allergy Clin. Immunol. 154, 101\u2013110 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR283","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","volume":"11","author":"ID Pavord","year":"2023","unstructured":"Pavord, I. D. et al. Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma. J. Allergy Clin. Immunol. Pract. 11, 1213\u20131220.e1212 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR284","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","volume":"77","author":"S Couillard","year":"2022","unstructured":"Couillard, S. et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax 77, 199\u2013202 (2022).","journal-title":"Thorax"},{"key":"2853_CR285","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","volume":"13","author":"FL Meulmeester","year":"2025","unstructured":"Meulmeester, F. L. et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir. Med. 13, 505\u2013516 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR286","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jaci.2014.09.034","volume":"135","author":"SJ Fowler","year":"2015","unstructured":"Fowler, S. J., Tavernier, G. & Niven, R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J. Allergy Clin. Immunol. 135, 822\u2013824 e822 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR287","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198\u20131207 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR288","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel, S. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455\u20132466 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR289","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price, D. B. et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir. Med. 3, 849\u2013858 (2015).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR290","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2024.06.008","volume":"128","author":"R Solans-Laque","year":"2024","unstructured":"Solans-Laque, R. et al. Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA). Eur. J. Intern Med. 128, 45\u201352 (2024).","journal-title":"Eur. J. Intern Med."},{"key":"2853_CR291","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1183\/09031936.06.00137704","volume":"27","author":"L Jayaram","year":"2006","unstructured":"Jayaram, L. et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 27, 483\u2013494 (2006).","journal-title":"Eur. Respir. J."},{"key":"2853_CR292","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","volume":"360","author":"RH Green","year":"2002","unstructured":"Green, R. H. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360, 1715\u20131721 (2002).","journal-title":"Lancet"},{"key":"2853_CR293","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/pai.12289","volume":"25","author":"AD Ro","year":"2014","unstructured":"Ro, A. D. et al. The predictive value of allergen skin prick tests and IgE tests at pre-school age: the PACT study. Pediatr. Allergy Immunol. 25, 691\u2013698 (2014).","journal-title":"Pediatr. Allergy Immunol."},{"key":"2853_CR294","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaci.2006.02.046","volume":"118","author":"G Takayama","year":"2006","unstructured":"Takayama, G. et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118, 98\u2013104 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR295","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.alit.2014.07.003","volume":"64","author":"M Matsusaka","year":"2015","unstructured":"Matsusaka, M. et al. Phenotype of asthma related with high serum periostin levels. Allergol. Int. 64, 175\u2013180 (2015).","journal-title":"Allergol. Int."},{"key":"2853_CR296","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1164\/rccm.201904-0733ED","volume":"200","author":"PJ Sterk","year":"2019","unstructured":"Sterk, P. J. Modern inflammatory phenotyping of asthma. Breathomics is here to stay. Am. J. Respir. Crit. Care Med. 200, 405\u2013406 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR297","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1056\/NEJMoa0708801","volume":"358","author":"C Ober","year":"2008","unstructured":"Ober, C. et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N. Engl. J. Med. 358, 1682\u20131691 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR298","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12931-016-0342-7","volume":"17","author":"T Shiobara","year":"2016","unstructured":"Shiobara, T. et al. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir. Res. 17, 28 (2016).","journal-title":"Respir. Res."},{"key":"2853_CR299","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12931-022-02211-6","volume":"23","author":"KC Gribben","year":"2022","unstructured":"Gribben, K. C. et al. CC16 polymorphisms in asthma, asthma subtypes, and asthma control in adults from the Agricultural Lung Health Study. Respir. Res. 23, 305 (2022).","journal-title":"Respir. Res."},{"key":"2853_CR300","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/cea.14315","volume":"53","author":"CG Jung","year":"2023","unstructured":"Jung, C. G. et al. Role of club cell 16-kDa secretory protein in asthmatic airways. Clin. Exp. Allergy 53, 648\u2013658 (2023).","journal-title":"Clin. Exp. Allergy"},{"key":"2853_CR301","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1165\/rcmb.2011-0391OC","volume":"46","author":"A Munitz","year":"2012","unstructured":"Munitz, A. et al. Resistin-like molecule-alpha regulates IL-13-induced chemokine production but not allergen-induced airway responses. Am. J. Respir. Cell Mol. Biol. 46, 703\u2013713 (2012).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2853_CR302","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","volume":"139","author":"D Lefaudeux","year":"2017","unstructured":"Lefaudeux, D. et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J. Allergy Clin. Immunol. 139, 1797\u20131807 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR303","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","volume":"181","author":"WC Moore","year":"2010","unstructured":"Moore, W. C. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 181, 315\u2013323 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR304","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S2213-2600(16)30048-0","volume":"4","author":"MC Peters","year":"2016","unstructured":"Peters, M. C. et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir. Med. 4, 574\u2013584 (2016).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR305","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rmed.2017.01.004","volume":"124","author":"SW Littleton","year":"2017","unstructured":"Littleton, S. W. & Tulaimat, A. The effects of obesity on lung volumes and oxygenation. Respir. Med. 124, 15\u201320 (2017).","journal-title":"Respir. Med."},{"key":"2853_CR306","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s10020-023-00702-w","volume":"29","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Wan, R. & Hu, C. Leptin\/obR signaling exacerbates obesity-related neutrophilic airway inflammation through inflammatory M1 macrophages. Mol. Med. 29, 100 (2023).","journal-title":"Mol. Med."},{"key":"2853_CR307","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107917","volume":"236","author":"M Belhassen","year":"2025","unstructured":"Belhassen, M. et al. In patients with asthma, obesity status is associated with poor control and high exacerbation rates, which are reversed after bariatric surgery. Respir. Med. 236, 107917 (2025).","journal-title":"Respir. Med."},{"key":"2853_CR308","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41533-018-0098-2","volume":"28","author":"B Aggarwal","year":"2018","unstructured":"Aggarwal, B., Mulgirigama, A. & Berend, N. Exercise-induced bronchoconstriction: prevalence, pathophysiology, patient impact, diagnosis and management. npj Prim. Care Respir. Med. 28, 31 (2018).","journal-title":"npj Prim. Care Respir. Med."},{"key":"2853_CR309","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaip.2024.11.005","volume":"13","author":"JK Cox","year":"2025","unstructured":"Cox, J. K., Lockey, R. & Cardet, J. C. Cough-variant asthma: a review of clinical characteristics, diagnosis, and pathophysiology. J. Allergy Clin. Immunol. Pract. 13, 490\u2013498 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR310","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaci.2023.04.017","volume":"152","author":"W Zhan","year":"2023","unstructured":"Zhan, W. et al. Identification of cough-variant asthma phenotypes based on clinical and pathophysiologic data. J. Allergy Clin. Immunol. 152, 622\u2013632 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR311","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jaci.2021.07.042","volume":"149","author":"K Shimizu","year":"2022","unstructured":"Shimizu, K. et al. Parenchymal destruction in asthma: fixed airflow obstruction and lung function trajectory. J. Allergy Clin. Immunol. 149, 934\u2013942.e938 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR312","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.jaci.2021.12.784","volume":"149","author":"S Rutting","year":"2022","unstructured":"Rutting, S., Tonga, K. O. & King, G. G. Toward explaining fixed airflow obstruction in asthma. J. Allergy Clin. Immunol. 149, 890\u2013892 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR313","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jaip.2025.05.002","volume":"13","author":"I Farinha","year":"2025","unstructured":"Farinha, I., Gibson, P. G., McDonald, V. M. & Heaney, L. G. Treatable traits as a pathway to remission in asthma. J. Allergy Clin. Immunol. Pract. 13, 1542\u20131552 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR314","doi-asserted-by":"publisher","first-page":"1834906","DOI":"10.3389\/fmed.2026.1834906","volume":"13","author":"C Xie","year":"2026","unstructured":"Xie, C. et al. Small airway dysfunction: a shared, early, measurable, and potentially treatable trait across COPD, asthma, and fibrotic lung disease. Front. Med. 13, 1834906 (2026).","journal-title":"Front. Med."},{"key":"2853_CR315","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","volume":"145","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow, A. et al. An expert consensus framework for asthma remission as a treatment goal. J. Allergy Clin. Immunol. 145, 757\u2013765 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR316","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","volume":"13","author":"C Porsbjerg","year":"2025","unstructured":"Porsbjerg, C. et al. Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage. Lancet Respir. Med. 13, 1026\u20131040 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR317","unstructured":"de Benedictis, F. M. et al. 50 years on: how inhaled corticosteroids have changed the treatment of asthma. Lancet Respir Med. S2213-2600, 00082-2 (2026)."},{"key":"2853_CR318","first-page":"107","volume":"8","author":"CK Kim","year":"2025","unstructured":"Kim, C. K. & Agrawal, D. K. Glucocorticoid insensitivity in severe asthma: underlying molecular mechanisms, challenges, and emerging therapies. Arch. Intern Med. Res. 8, 107\u2013120 (2025).","journal-title":"Arch. Intern Med. Res."},{"key":"2853_CR319","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1465-9921-7-13","volume":"7","author":"ED Bateman","year":"2006","unstructured":"Bateman, E. D., Fairall, L., Lombardi, D. M. & English, R. Budesonide\/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir. Res. 7, 13 (2006).","journal-title":"Respir. Res."},{"key":"2853_CR320","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/thx.2009.128504","volume":"65","author":"KR Chapman","year":"2010","unstructured":"Chapman, K. R. et al. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 65, 747\u2013752 (2010).","journal-title":"Thorax"},{"key":"2853_CR321","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","volume":"380","author":"R Beasley","year":"2019","unstructured":"Beasley, R. et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N. Engl. J. Med. 380, 2020\u20132030 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR322","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0615","volume":"5","author":"R Beasley","year":"2022","unstructured":"Beasley, R. et al. Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis. JAMA Netw. Open 5, e220615 (2022).","journal-title":"JAMA Netw. Open"},{"key":"2853_CR323","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pupt.2008.11.010","volume":"22","author":"C Cote","year":"2009","unstructured":"Cote, C., Pearle, J. L., Sharafkhaneh, A. & Spangenthal, S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm. Pharm. Ther. 22, 44\u201349 (2009).","journal-title":"Pulm. Pharm. Ther."},{"key":"2853_CR324","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/JAA.S283489","volume":"15","author":"P Rogliani","year":"2022","unstructured":"Rogliani, P. et al. Potential drawbacks of ICS\/LABA\/LAMA triple fixed-dose combination therapy in the treatment of asthma: a quantitative synthesis of safety profile. J. Asthma Allergy 15, 565\u2013577 (2022).","journal-title":"J. Asthma Allergy"},{"key":"2853_CR325","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee, L. A. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir. Med. 9, 69\u201384 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR326","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow, J. C. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 394, 1737\u20131749 (2019).","journal-title":"Lancet"},{"key":"2853_CR327","doi-asserted-by":"crossref","unstructured":"Rogliani, P., Ritondo, B. L. & Calzetta, L. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 58, 2004233 (2021).","DOI":"10.1183\/13993003.04233-2020"},{"key":"2853_CR328","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel, E. H. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189\u20131197 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR329","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair, P. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 376, 2448\u20132458 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR330","doi-asserted-by":"crossref","unstructured":"Menzies-Gow, A. et al. Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study. Eur Respir J. 60, 2103226 (2022).","DOI":"10.1183\/13993003.03226-2021"},{"key":"2853_CR331","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe, K. F. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N. Engl. J. Med. 378, 2475\u20132485 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR332","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-2600(25)00359-5","volume":"14","author":"DJ Jackson","year":"2026","unstructured":"Jackson, D. J. et al. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. Lancet Respir. Med. 14, 129\u2013140 (2026).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR333","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41577-022-00786-1","volume":"23","author":"SR Durham","year":"2023","unstructured":"Durham, S. R. & Shamji, M. H. Allergen immunotherapy: past, present and future. Nat. Rev. Immunol. 23, 317\u2013328 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2853_CR334","doi-asserted-by":"publisher","first-page":"1032909","DOI":"10.3389\/fimmu.2022.1032909","volume":"13","author":"L Qin","year":"2022","unstructured":"Qin, L., Tang, L. F., Cheng, L. & Wang, H. Y. The clinical significance of allergen-specific IgG4 in allergic diseases. Front Immunol. 13, 1032909 (2022).","journal-title":"Front Immunol."},{"key":"2853_CR335","doi-asserted-by":"publisher","DOI":"10.1186\/s40413-015-0063-2","volume":"8","author":"CA Akdis","year":"2015","unstructured":"Akdis, C. A. & Akdis, M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 8, 17 (2015).","journal-title":"World Allergy Organ J."},{"key":"2853_CR336","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/all.13208","volume":"72","author":"S Dhami","year":"2017","unstructured":"Dhami, S. et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 72, 1825\u20131848 (2017).","journal-title":"Allergy"},{"key":"2853_CR337","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1164\/rccm.201911-2298OC","volume":"203","author":"AWM Goorsenberg","year":"2021","unstructured":"Goorsenberg, A. W. M. et al. Bronchial thermoplasty induced airway smooth muscle reduction and clinical response in severe asthma. The TASMA randomized trial. Am. J. Respir. Crit. Care Med. 203, 175\u2013184 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR338","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/thorax-2023-220967","volume":"79","author":"PC Wijsman","year":"2024","unstructured":"Wijsman, P. C. et al. Airway smooth muscle and long-term clinical efficacy following bronchial thermoplasty in severe asthma. Thorax 79, 359\u2013362 (2024).","journal-title":"Thorax"},{"key":"2853_CR339","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa064707","volume":"356","author":"G Cox","year":"2007","unstructured":"Cox, G. et al. Asthma control during the year after bronchial thermoplasty. N. Engl. J. Med. 356, 1327\u20131337 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR340","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","volume":"181","author":"M Castro","year":"2010","unstructured":"Castro, M. et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am. J. Respir. Crit. Care Med. 181, 116\u2013124 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR341","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-2600(20)30408-2","volume":"9","author":"R Chaudhuri","year":"2021","unstructured":"Chaudhuri, R. et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir. Med. 9, 457\u2013466 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR342","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jaci.2023.09.035","volume":"153","author":"PC Wijsman","year":"2024","unstructured":"Wijsman, P. C. et al. Airway wall extracellular matrix changes induced by bronchial thermoplasty in severe asthma. J. Allergy Clin. Immunol. 153, 435\u2013446.e434 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR343","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20797","volume":"9","author":"X Liao","year":"2023","unstructured":"Liao, X. et al. An underlying mechanism behind interventional pulmonology techniques for refractory asthma treatment: Neuro-immunity crosstalk. Heliyon 9, e20797 (2023).","journal-title":"Heliyon"},{"key":"2853_CR344","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/atm.ATM_365_17","volume":"13","author":"F Nasim","year":"2018","unstructured":"Nasim, F. & Iyer, V. N. Bronchial thermoplasty-an update. Ann. Thorac. Med. 13, 205\u2013211 (2018).","journal-title":"Ann. Thorac. Med."},{"key":"2853_CR345","doi-asserted-by":"publisher","first-page":"147997312513669","DOI":"10.1177\/14799731251366969","volume":"22","author":"HWW Aung","year":"2025","unstructured":"Aung, H. W. W., Murphy, A. & Greening, N. J. The evolving landscape of digital inhaler platforms and adherence support in chronic airways disease. Chron. Respir. Dis. 22, 14799731251366969 (2025).","journal-title":"Chron. Respir. Dis."},{"key":"2853_CR346","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","volume":"406","author":"E Israel","year":"2025","unstructured":"Israel, E., Wechsler, M. E., Jackson, D. J. & Moore, W. C. Anti-cytokine biologics for asthma in adults. Lancet 406, 2282\u20132294 (2025).","journal-title":"Lancet"},{"key":"2853_CR347","doi-asserted-by":"crossref","unstructured":"Gyawali, B., Georas, S. N. & Khurana, S. Biologics in severe asthma: a state-of-the-art review. Eur. Respir Rev. 34, 240088 (2025).","DOI":"10.1183\/16000617.0088-2024"},{"key":"2853_CR348","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.4049\/jimmunol.1601476","volume":"197","author":"T Kawakami","year":"2016","unstructured":"Kawakami, T. & Blank, U. From IgE to Omalizumab. J. Immunol. 197, 4187\u20134192 (2016).","journal-title":"J. Immunol."},{"key":"2853_CR349","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11610","volume":"7","author":"LF Pennington","year":"2016","unstructured":"Pennington, L. F. et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat. Commun. 7, 11610 (2016).","journal-title":"Nat. Commun."},{"key":"2853_CR350","doi-asserted-by":"crossref","unstructured":"Humbert, M. et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur. Respir. J. 51, 1702523 (2018).","DOI":"10.1183\/13993003.02523-2017"},{"key":"2853_CR351","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","volume":"9","author":"J Bousquet","year":"2021","unstructured":"Bousquet, J. et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J. Allergy Clin. Immunol. Pract. 9, 2702\u20132714 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR352","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13223-020-00442-0","volume":"16","author":"DP Henriksen","year":"2020","unstructured":"Henriksen, D. P. et al. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin. Immunol. 16, 49 (2020).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"2853_CR353","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1183\/09059180.00010403","volume":"16","author":"R Buhl","year":"2007","unstructured":"Buhl, R. Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy. Eur. Respir. Rev. 16, 73\u201377 (2007).","journal-title":"Eur. Respir. Rev."},{"key":"2853_CR354","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100787","volume":"16","author":"F Menzella","year":"2023","unstructured":"Menzella, F. et al. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU\/mL. World Allergy Organ J. 16, 100787 (2023).","journal-title":"World Allergy Organ J."},{"key":"2853_CR355","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/all.16303","volume":"79","author":"KM Buchheit","year":"2024","unstructured":"Buchheit, K. M. et al. Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: effects on and beyond eosinophils. Allergy 79, 2662\u20132679 (2024).","journal-title":"Allergy"},{"key":"2853_CR356","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651\u2013659 (2012).","journal-title":"Lancet"},{"key":"2853_CR357","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald, J. M. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388, 2128\u20132141 (2016).","journal-title":"Lancet"},{"key":"2853_CR358","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker, E. R. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388, 2115\u20132127 (2016).","journal-title":"Lancet"},{"key":"2853_CR359","doi-asserted-by":"crossref","unstructured":"Huang, W. C. et al. Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study. BMC Pulm Med. 26, 116 (2026).","DOI":"10.1186\/s12890-026-04158-6"},{"key":"2853_CR360","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega, H. G. et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir. Med. 4, 549\u2013556 (2016).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR361","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h, A. et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy 75, 1188\u20131204 (2020).","journal-title":"Allergy"},{"key":"2853_CR362","doi-asserted-by":"crossref","unstructured":"Sandhu, E. et al. Dupilumab reduces mucus radiodensity and new plug formation in asthma. Chest S0012-3692, 00465-4 (2026).","DOI":"10.1016\/j.chest.2026.03.041"},{"key":"2853_CR363","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","volume":"75","author":"K Bao","year":"2015","unstructured":"Bao, K. & Reinhardt, R. L. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine 75, 25\u201337 (2015).","journal-title":"Cytokine"},{"key":"2853_CR364","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12016-025-09045-2","volume":"68","author":"L Sahnoon","year":"2025","unstructured":"Sahnoon, L. et al. Targeting IL-13 and IL-4 in asthma: therapeutic implications on airway remodeling in severe asthma. Clin. Rev. Allergy Immunol. 68, 44 (2025).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2853_CR365","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro, M. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378, 2486\u20132496 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR366","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","volume":"13","author":"ID Pavord","year":"2025","unstructured":"Pavord, I. D. et al. Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma. J. Allergy Clin. Immunol. Pract. 13, 132\u2013142 (2025).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR367","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","volume":"35","author":"WW Busse","year":"2018","unstructured":"Busse, W. W. et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma. Adv. Ther. 35, 737\u2013748 (2018).","journal-title":"Adv. Ther."},{"key":"2853_CR368","doi-asserted-by":"crossref","unstructured":"Wechsler, M. E. et al. Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics. ERJ Open Res. 10, 00188\u20132024 (2024).","DOI":"10.1183\/23120541.00188-2024"},{"key":"2853_CR369","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert, C. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394, 1638\u20131650 (2019).","journal-title":"Lancet"},{"key":"2853_CR370","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","volume":"150","author":"KM Buchheit","year":"2022","unstructured":"Buchheit, K. M. et al. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 150, 415\u2013424 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR371","doi-asserted-by":"crossref","unstructured":"Schneider, S. et al. Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease. Eur. Respir. J. 61, 2201335 (2023).","DOI":"10.1183\/13993003.01335-2022"},{"key":"2853_CR372","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","volume":"365","author":"J Corren","year":"2011","unstructured":"Corren, J. et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088\u20131098 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR373","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","volume":"70","author":"NA Hanania","year":"2015","unstructured":"Hanania, N. A. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70, 748\u2013756 (2015).","journal-title":"Thorax"},{"key":"2853_CR374","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","volume":"6","author":"RA Panettieri Jr","year":"2018","unstructured":"Panettieri, R. A. Jr et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir. Med. 6, 511\u2013525 (2018).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR375","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2023","unstructured":"Ebina-Shibuya, R. & Leonard, W. J. Role of thymic stromal lymphopoietin in allergy and beyond. Nat. Rev. Immunol. 23, 24\u201337 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2853_CR376","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow, A. et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N. Engl. J. Med. 384, 1800\u20131809 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR377","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","volume":"208","author":"J Corren","year":"2023","unstructured":"Corren, J. et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am. J. Respir. Crit. Care Med. 208, 13\u201324 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR378","doi-asserted-by":"crossref","unstructured":"Khateeb, J. et al. Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort. ERJ Open Res. 11, 00314\u20132025 (2025).","DOI":"10.1183\/23120541.00314-2025"},{"key":"2853_CR379","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler, M. E. et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N. Engl. J. Med. 385, 1656\u20131668 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR380","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen, S. G. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J. Allergy Clin. Immunol. 148, 790\u2013798 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR381","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.jaci.2017.07.051","volume":"141","author":"RB Werder","year":"2018","unstructured":"Werder, R. B. et al. Chronic IL-33 expression predisposes to virus-induced asthma exacerbations by increasing type 2 inflammation and dampening antiviral immunity. J. Allergy Clin. Immunol. 141, 1607\u20131619.e1609 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR382","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbrc.2018.08.064","volume":"504","author":"S Venkataramani","year":"2018","unstructured":"Venkataramani, S. et al. Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP\/IL13 bispecific antibodies. Biochem Biophys. Res Commun. 504, 19\u201324 (2018).","journal-title":"Biochem Biophys. Res Commun."},{"key":"2853_CR383","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13864","volume":"17","author":"A Deiteren","year":"2024","unstructured":"Deiteren, A. et al. A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY(R) compound, in healthy volunteers. Clin. Transl. Sci. 17, e13864 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"2853_CR384","doi-asserted-by":"crossref","unstructured":"Deiteren, A. et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. Eur. Respir. J. 65, 2401461 (2025).","DOI":"10.1183\/13993003.01461-2024"},{"key":"2853_CR385","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu3759","volume":"17","author":"S Asrat","year":"2025","unstructured":"Asrat, S. et al. The IL-33 and IL-4Ralpha blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma. Sci. Transl. Med. 17, eadu3759 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2853_CR386","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","volume":"142","author":"M Godar","year":"2018","unstructured":"Godar, M. et al. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J. Allergy Clin. Immunol. 142, 1185\u20131193.e1184 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR387","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1183\/09031936.00123612","volume":"41","author":"A Kirsten","year":"2013","unstructured":"Kirsten, A. et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers. Eur. Respir. J. 41, 239\u2013241 (2013).","journal-title":"Eur. Respir. J."},{"key":"2853_CR388","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","volume":"385","author":"CE Brightling","year":"2021","unstructured":"Brightling, C. E. et al. Risankizumab in severe asthma - a phase 2a, placebo-controlled trial. N. Engl. J. Med. 385, 1669\u20131679 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR389","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/thx.2007.086314","volume":"63","author":"JB Morjaria","year":"2008","unstructured":"Morjaria, J. B. et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 63, 584\u2013591 (2008).","journal-title":"Thorax"},{"key":"2853_CR390","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2024.12.002","volume":"81","author":"NZ Bouzeineddine","year":"2025","unstructured":"Bouzeineddine, N. Z., Philippi, A., Gee, K. & Basta, S. Granulocyte macrophage colony stimulating factor in virus-host interactions and its implication for immunotherapy. Cytokine Growth Factor Rev. 81, 54\u201363 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2853_CR391","doi-asserted-by":"publisher","first-page":"e007709","DOI":"10.1136\/bmjopen-2015-007709","volume":"6","author":"NA Molfino","year":"2016","unstructured":"Molfino, N. A. et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open 6, e007709 (2016).","journal-title":"BMJ Open"},{"key":"2853_CR392","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jaip.2019.02.043","volume":"7","author":"B Esty","year":"2019","unstructured":"Esty, B. et al. Treatment of severe persistent asthma with IL-6 receptor blockade. J. Allergy Clin. Immunol. Pract. 7, 1639\u20131642.e1634 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR393","doi-asserted-by":"crossref","unstructured":"Doffman, S. R. et al. AZD8630\/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial. J. Allergy Clin. Immunol. S0091-6749, 00262-9 (2026).","DOI":"10.1016\/j.jaci.2026.03.026"},{"key":"2853_CR394","doi-asserted-by":"crossref","unstructured":"Bateman, E. D. et al. Fevipiprant, an oral prostaglandin DP(2) receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur. Respir. J. 50, 1700670 (2017).","DOI":"10.1183\/13993003.00670-2017"},{"key":"2853_CR395","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12931-021-01904-8","volume":"22","author":"J Maspero","year":"2021","unstructured":"Maspero, J. et al. Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial. Respir. Res. 22, 311 (2021).","journal-title":"Respir. Res."},{"key":"2853_CR396","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","volume":"77","author":"M Kupczyk","year":"2017","unstructured":"Kupczyk, M. & Kuna, P. Targeting the PGD(2)\/CRTH2\/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. Drugs 77, 1281\u20131294 (2017).","journal-title":"Drugs"},{"key":"2853_CR397","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11868-9","volume":"7","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma. Sci. Rep. 7, 15038 (2017).","journal-title":"Sci. Rep."},{"key":"2853_CR398","first-page":"770","volume":"12","author":"SA Antoniu","year":"2010","unstructured":"Antoniu, S. A. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr. Opin. Mol. Ther. 12, 770\u2013779 (2010).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"2853_CR399","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S2213-2600(25)00439-4","volume":"14","author":"JF Maspero","year":"2026","unstructured":"Maspero, J. F. et al. Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study. Lancet Respir. Med. 14, 405\u2013416 (2026).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR400","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1600-065X.2008.00742.x","volume":"228","author":"AM Gilfillan","year":"2009","unstructured":"Gilfillan, A. M. & Rivera, J. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 228, 149\u2013169 (2009).","journal-title":"Immunol. Rev."},{"key":"2853_CR401","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel, J. et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am. J. Hematol. 93, 921\u2013930 (2018).","journal-title":"Am. J. Hematol."},{"issue":"Suppl 1","key":"2853_CR402","doi-asserted-by":"publisher","first-page":"i77","DOI":"10.1136\/ard.2009.119479","volume":"69","author":"D Hammaker","year":"2010","unstructured":"Hammaker, D. & Firestein, G. S. \u201cGo upstream, young man\u201d: lessons learned from the p38 saga. Ann. Rheum. Dis. 69(Suppl 1), i77\u201382 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"2853_CR403","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2147\/COPD.S150576","volume":"13","author":"NR Patel","year":"2018","unstructured":"Patel, N. R. et al. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J. Chron. Obstruct Pulmon Dis. 13, 1009\u20131019 (2018).","journal-title":"Int J. Chron. Obstruct Pulmon Dis."},{"key":"2853_CR404","doi-asserted-by":"publisher","first-page":"115973","DOI":"10.1016\/j.bcp.2023.115973","volume":"220","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Function and inhibition of P38 MAP kinase signaling: targeting multiple inflammation diseases. Biochem Pharm. 220, 115973 (2024).","journal-title":"Biochem Pharm."},{"key":"2853_CR405","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1016\/j.jaip.2021.07.007","volume":"9","author":"TD Wu","year":"2021","unstructured":"Wu, T. D. et al. Metformin use and risk of asthma exacerbation among asthma patients with glycemic dysfunction. J. Allergy Clin. Immunol. Pract. 9, 4014\u20134020 e4014 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"2853_CR406","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.jaci.2017.05.033","volume":"140","author":"M Kaler","year":"2017","unstructured":"Kaler, M. et al. A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma. J. Allergy Clin. Immunol. 140, 1716\u20131718 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2853_CR407","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/1744666X.2021.1971973","volume":"17","author":"AY Wu","year":"2021","unstructured":"Wu, A. Y. & Peebles, R. S. The GLP-1 receptor in airway inflammation in asthma: a promising novel target? Expert Rev. Clin. Immunol. 17, 1053\u20131057 (2021).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2853_CR408","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1111\/all.14879","volume":"76","author":"S Toki","year":"2021","unstructured":"Toki, S. et al. Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice. Allergy 76, 3433\u20133445 (2021).","journal-title":"Allergy"},{"key":"2853_CR409","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s41030-022-00203-x","volume":"8","author":"AG Kaplan","year":"2022","unstructured":"Kaplan, A. G. & Kim, J. W. Asthma exacerbations and glucagon-like peptide-1 receptor agonists: a review of the current evidence. Pulm. Ther. 8, 343\u2013358 (2022).","journal-title":"Pulm. Ther."},{"key":"2853_CR410","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1513\/AnnalsATS.202309-836OC","volume":"21","author":"T Wang","year":"2024","unstructured":"Wang, T. et al. Glucagon-like peptide 1 receptor agonists and asthma exacerbations: which patients benefit most? Ann. Am. Thorac. Soc. 21, 1496\u20131506 (2024).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2853_CR411","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1007\/s12325-025-03175-x","volume":"42","author":"A Kaplan","year":"2025","unstructured":"Kaplan, A. et al. The real-world impact of glucagon-like peptide 1 receptor agonists on asthma control in people with high-risk asthma and obesity. Adv. Ther. 42, 2950\u20132956 (2025).","journal-title":"Adv. Ther."},{"key":"2853_CR412","doi-asserted-by":"crossref","unstructured":"de Boer, G. M. et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. Eur. Respir Rev. 29, 190175 (2020).","DOI":"10.1183\/16000617.0175-2019"},{"key":"2853_CR413","doi-asserted-by":"publisher","first-page":"e14186","DOI":"10.1111\/pai.14186","volume":"35","author":"JA Castro-Rodriguez","year":"2024","unstructured":"Castro-Rodriguez, J. A., Turi, K. N. & Forno, E. A critical analysis of the effect of OM-85 for the prevention of recurrent respiratory tract infections or wheezing\/asthma from systematic reviews with meta-analysis. Pediatr. Allergy Immunol. 35, e14186 (2024).","journal-title":"Pediatr. Allergy Immunol."},{"key":"2853_CR414","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/cea.13990","volume":"51","author":"GM de Boer","year":"2021","unstructured":"de Boer, G. M. et al. Bacterial lysate add-on therapy to reduce exacerbations in severe asthma: a double-blind placebo-controlled trial. Clin. Exp. Allergy 51, 1172\u20131184 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"2853_CR415","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41421-022-00433-y","volume":"8","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. Cell Discov. 8, 80 (2022).","journal-title":"Cell Discov."},{"key":"2853_CR416","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-021-00482-x","volume":"6","author":"X Du","year":"2021","unstructured":"Du, X. et al. Eosinophil-derived chemokine (hCCL15\/23, mCCL6) interacts with CCR1 to promote eosinophilic airway inflammation. Signal Transduct. Target Ther. 6, 91 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2853_CR417","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41590-024-01834-9","volume":"25","author":"G Jin","year":"2024","unstructured":"Jin, G. et al. A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. Nat. Immunol. 25, 1059\u20131072 (2024).","journal-title":"Nat. Immunol."},{"key":"2853_CR418","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05534-8","volume":"22","author":"M Mohammad Taheri","year":"2024","unstructured":"Mohammad Taheri, M., Javan, F., Poudineh, M. & Athari, S. S. Beyond CAR-T: the rise of CAR-NK cell therapy in asthma immunotherapy. J. Transl. Med. 22, 736 (2024).","journal-title":"J. Transl. Med."},{"key":"2853_CR419","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","volume":"8","author":"J Skuljec","year":"2017","unstructured":"Skuljec, J. et al. Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma. Front. Immunol. 8, 1125 (2017).","journal-title":"Front. Immunol."},{"key":"2853_CR420","doi-asserted-by":"publisher","first-page":"963689723118012","DOI":"10.1177\/09636897231180128","volume":"32","author":"S Huang","year":"2023","unstructured":"Huang, S. et al. Mesenchymal stem\/stromal cells in asthma therapy: mechanisms and strategies for enhancement. Cell Transpl. 32, 9636897231180128 (2023).","journal-title":"Cell Transpl."},{"key":"2853_CR421","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1443166","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. MiR-146a-5p engineered hucMSC-derived extracellular vesicles attenuate Dermatophagoides farinae-induced allergic airway epithelial cell inflammation. Front. Immunol. 15, 1443166 (2024).","journal-title":"Front. Immunol."},{"key":"2853_CR422","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1411776","volume":"372","author":"N Krug","year":"2015","unstructured":"Krug, N. et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N. Engl. J. Med. 372, 1987\u20131995 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2853_CR423","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jconrel.2022.10.020","volume":"352","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment. J. Control Release 352, 422\u2013437 (2022).","journal-title":"J. Control Release"},{"key":"2853_CR424","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41434-025-00564-3","volume":"32","author":"S Kumar","year":"2025","unstructured":"Kumar, S. et al. AAV-mediated MUC5AC siRNA delivery to prevent mucociliary dysfunction in asthma. Gene Ther. 32, 508\u2013516 (2025).","journal-title":"Gene Ther."},{"key":"2853_CR425","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/all.15666","volume":"78","author":"BS Stikker","year":"2023","unstructured":"Stikker, B. S., Hendriks, R. W. & Stadhouders, R. Decoding the genetic and epigenetic basis of asthma. Allergy 78, 940\u2013956 (2023).","journal-title":"Allergy"},{"key":"2853_CR426","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","volume":"210","author":"L Perez-de-Llano","year":"2024","unstructured":"Perez-de-Llano, L. et al. Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am. J. Respir. Crit. Care Med. 210, 869\u2013880 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2853_CR427","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","volume":"397","author":"J Meghji","year":"2021","unstructured":"Meghji, J. et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet 397, 928\u2013940 (2021).","journal-title":"Lancet"},{"key":"2853_CR428","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S2213-2600(24)00383-7","volume":"13","author":"SM Jayasooriya","year":"2025","unstructured":"Jayasooriya, S. M. et al. Asthma: epidemiology, risk factors, and opportunities for prevention and treatment. Lancet Respir. Med. 13, 725\u2013738 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR429","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2105\/AJPH.2013.301695","volume":"104","author":"DA Turcotte","year":"2014","unstructured":"Turcotte, D. A. et al. Healthy homes: in-home environmental asthma intervention in a diverse urban community. Am. J. Public Health 104, 665\u2013671 (2014).","journal-title":"Am. J. Public Health"},{"key":"2853_CR430","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12931-025-03356-w","volume":"26","author":"C Xie","year":"2025","unstructured":"Xie, C. et al. Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits. Respir. Res 26, 274 (2025).","journal-title":"Respir. Res"},{"key":"2853_CR431","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert, M. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment). Innovate. Allergy 60, 309\u2013316 (2005).","journal-title":"Innovate. Allergy"},{"key":"2853_CR432","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","volume":"154","author":"NA Hanania","year":"2011","unstructured":"Hanania, N. A. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern Med. 154, 573\u2013582 (2011).","journal-title":"Ann. Intern Med."},{"key":"2853_CR433","doi-asserted-by":"crossref","unstructured":"Moore, W. C. et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur. Respir J. 59, 2100396 (2022).","DOI":"10.1183\/13993003.00396-2021"},{"key":"2853_CR434","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro, M. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355\u2013366 (2015).","journal-title":"Lancet Respir. Med."},{"key":"2853_CR435","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren, J. et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 150, 799\u2013810 (2016).","journal-title":"Chest"},{"key":"2853_CR436","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer, L. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 150, 789\u2013798 (2016).","journal-title":"Chest"},{"key":"2853_CR437","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler, M. E. et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir. Med. 10, 650\u2013660 (2022).","journal-title":"Lancet Respir. Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02853-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02853-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02853-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:02:25Z","timestamp":1786320145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02853-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":437,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2853"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02853-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"317"}}